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ABSTRACT 
 
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable 
chronic airway disease (CAD) and is the 4th leading cause of illness and death worldwide. 
CAD represents a group of diseases with different clinical phenotypes, airway inflammation, 
obstruction and destruction of the lung parenchyma. COPD is a heterogeneous disease, which 
is characterized by persistent respiratory symptoms and airflow limitation and its prevalence 
varies considerably across populations. Asthma-COPD overlap syndrome (ACOS) had been 
reported in 2009 and recognised by Global Initiative for Asthma (GINA) and Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) in 2014. ACOS is identified by the features 
that it shares with both asthma and COPD. Inhaling tobacco smoke is the main risk for CAD, 
thus smoking cessation is not only the key step for prevention and maintenance therapy for 
COPD (GOLD 2017), but also it is encouraged in the patient with asthma and their families 
(GINA 2017). Smoking cessation, pulmonary rehabilitation, pharmacologic therapy and the 
other therapies for COPD may improve symptoms, health status and exercise ability and reduce 
frequency of exacerbations (GOLD 2017). At present, COPD is generally diagnosed by lung 
function measurement using spirometry, but not all individuals presenting with airflow 
limitation follow the paradigm. On the individual level spirometry may poorly correlate with 
symptoms, risk of exacerbation, prognosis and response to treatment in COPD. Due to disease 
heterogeneity, limitations of spirometry and lack of predictive molecular markers, the 
mechanisms underlying different COPD phenotypes are still unclear. Therefore, identification 
of the similarities and differences of COPD clinical phenotypes is important, as these 
phenotypes require different therapeutic approaches and have distinct clinical outcomes. We 
hypothesised that the potential biomarkers may play an important role and even predict the 
development of COPD. Accordingly, patients with asthma, COPD and ACOS would exhibit 
different biomarker profiles. Furthermore, distinguishing COPD phenotypes via distinct 
molecular and cellular pathways may facilitate the development of individualised diagnosis 
and precision medicine.  
 
The first goal of this study was to identify COPD-specific proteomic changes involved in 
disease onset and severity. The second goal was to identify novel biomarkers for the clinical 
COPD phenotypes in smokers and patients with COPD, asthma and ACOS in cross-sectional 
and longitudinal studies. The third goal was to investigate whether the levels of these markers 
are associated with variables such as pack-years, lung function and sputum cell profiles. Finally, 
we aimed to evaluate the association of the biomarker levels with a longitudinal decline of lung 
function. Those studies included the 6-year longitudinal cohort of adult smokers for early 
diagnosis of COPD studies (Study I, II and III), and the Finnish discovery cohort and the 
Japanese replication cohort for ACOS studies (Study IV and V). 
 
 
 
We selected biomarkers identified in our non-hypothesis-based proteomic approaches for early 
COPD diagnosis, such as transglutaminase 2 (TGM2), bactericidal/permeability-increasing 
(BPI) fold-containing protein B1 (BPIFB1) and soluble receptor for advanced glycation end-
products (sRAGE). Based on our previous results and non-hypothesis-based proteomic 
approaches, we developed two panels of potential biomarkers for ACOS: COPD-related 
biomarkers and asthma-related biomarkers. The four COPD-related biomarkers are neutrophil 
gelatinase-associated lipocalin (NGAL), myeloperoxidase (MPO), surfactant protein A (SP-A) 
and sRAGE. The three asthma-related biomarkers are chitinase-like protein YKL-40 (YKL-
40), interleukin-6 (IL-6) and interleukin IL-13 (IL-13). 
 
For the early COPD diagnosis studies, induced sputum and plasma samples were categorised 
into 3 groups: non-smokers, smokers without COPD and smokers with COPD (stable stage I 
and stage II-III). Lung tissue samples were obtained from non-smokers, smokers without 
COPD, smokers with COPD and patients with idiopathic pulmonary fibrosis (IPF). For the 
ACOS studies, induced sputum and plasma samples were categorised into 5 groups: non-
smokers, healthy smokers, patients with asthma, COPD and ACOS. Sputum cell counts were 
evaluated from sputum cytospins.  TGM2 and BPIFB1 were assessed by Western blot analysis 
and by cysteine-specific two-dimensional difference gel electrophoresis (2D-DIGE) coupled 
with mass spectrometry (MS). BPIFB1 was further detected by immunohistochemistry and 
functional enzyme-linked immunosorbent assay (ELISA). TGM2, sRAGE, NGAL, MPO, SP-
A, YKL-40, IL-6 and IL-13 levels were measured by commercial ELISA or Magnetic Human 
High Sensitivity Luminex assay (Luminex assay). 
 
Our results showed that TGM2 levels in sputum and plasma were elevated in mild-moderate 
COPD and associated with lung function. Sputum BPIFB1 levels were elevated in smokers 
with COPD, whereas plasma sRAGE levels were decreased in smokers without COPD and 
smokers with COPD. Sputum BPIFB1 and plasma sRAGE levels were significantly associated 
with reduced airflow limitation over time in smokers with COPD. In the Finnish discovery 
cohort of the ACOS study, sputum MPO and plasma SP-A levels were significantly elevated 
in ACOS, whereas plasma sRAGE levels were decreased in ACOS.  Sputum IL-13 levels were 
increased in ACOS when compared with controls. Sputum YKL-40 and IL-6 differentiated 
ACOS from COPD and asthma based on receiver operating characteristic (ROC) curve analysis. 
However, only sputum NGAL results could be repeated from the Finnish discovery cohort to 
Japanese replication cohort. Importantly, NGAL differentiated ACOS from COPD and 
independently correlated with forced expiratory volume in one second % (FEV1% predicted) 
in both cohorts. 
 
In conclusion, our findings support the hypothesis that monitoring of these biomarkers may be 
useful for differential diagnosis between the clinical phenotypes of COPD. TGM2 may be a 
 
 
potential diagnostic and therapeutic marker in COPD, which may relate to COPD onset and 
severity. BPIFB1 and sRAGE play vital roles in the pathogenesis of smoking-related COPD. 
High concentrations of sRAGE might be involved in the protective role of the airway. Patients 
with COPD and ACOS exhibit different NGAL profiles in sputum. These findings suggest that 
these potential biomarkers could be a novel diagnostic and therapeutic target for COPD. On 
the other hand, sputum biomarkers reflect both airway inflammation and tissue remodelling, 
and monitoring these biomarkers may be useful for differential diagnosis between asthma, 
COPD and ACOS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIIVISTELMÄ 
 
Keuhkoahtaumatauti (COPD) on yleinen estettävissä ja hoidettavissa oleva keuhkosairaus, 
jonka taudinkuva vaihtelee huomattavasti eri potilaiden välillä. Taudille tyypillisiä yhdistäviä 
tekijöitä ovat pitkittyneet hengitystieoireet sekä ilmateiden pysyvä ahtauma. Tupakasta 
vieroituksella, liikuntaharjoitteluun perustuvalla kuntoutuksella ja lääkehoidolla voidaan 
helpottaa oireita, parantaa potilaan yleistä terveyden tilaa sekä vähentää pahenemisvaiheita. 
Keuhkoahtaumataudin diagnoosi perustuu nykyisin spirometriatutkimuksiin, joilla mitataan 
potilaan hengityskapasiteettia. Menetelmällä saadut tulokset kuitenkin poikkeavat viitearvoista 
vasta siinä vaiheessa, kun tauti on jo edennyt pitkälle. Spirometrialla ei myöskään saada tietoa 
taudinkuvasta ja ennusteesta. Tämän vuoksi olisi tärkeää löytää ennustavia tekijöitä 
keuhkoahtaumataudin varhaisempaan toteamiseen ja sen erilaisten taudinmuotojen 
toteamiseen. Yksi näistä on sekamuotoinen astma-keuhkoahtaumatauti (ACOS), jonka 
taudinkuva on huonompi kuin pelkän keuhkoahtaumataudin. Hypoteesimme mukaan verestä 
tai ysköksestä mitattavia yhdisteitä (biomarkkereita) voidaan hyödyntää taudin 
diagnosoinnissa, seurannassa ja taudinkulun ennustamisessa. 
 
Tämän tutkimuksen ensimmäisen osatyön tavoitteena oli löytää proteiiniprofiilien 
seulontamenetelmän (proteomiikka) avulla keuhkoahtaumataudin puhkeamiseen ja taudin 
vaikeusasteeseen liittyviä täysin uusia biomarkkereita. Seuraavissa osatöissä hyödynnettiin 
aiemmin löydettyjä biomarkkereita keuhkoahtaumataudin erilaisten alamuotojen 
tunnistamisessa käyttäen tupakoitsijoilta sekä astma-, keuhkoahtaumatauti- ja ACOS-potilailta 
kerättyjä plasma- ja yskösnäytteitä. Lisäksi tavoitteena oli selvittää löydettyjen biomarkkerien 
ja taudin ilmiasuun liittyvien kliinisten ominaisuuksien välisiä yhteyksiä. 
 
Proteomiikan ja kirjallisuushakujen perusteella valitsimme TGM2, BPIFB1 ja sRAGE 
proteiinit biomarkkereiksi ja selvitimme niiden toimivuutta keuhkoahtaumataudin varhaisessa 
tunnistamisessa. Lisäksi selvitimme, voidaanko keuhkoahtaumatautiin (NGAL, MPO, SP-A 
and sRAGE) ja astmaan aiemmin yhdistettyjä biomarkkereita (YKL-40, IL-6 and IL-13) 
käyttää ACOS:n tunnistamiseen.  
 
Tulostemme perusteella yskös- ja plasmanäytteiden TGM2:n pitoisuudet olivat koholla 
keuhkoahtaumataudissa ja liittyivät taudin vaikeusasteeseen. Yskösten BPIFB1:n pitoisuudet 
olivat nousseet tupakoivilla keuhkoahtaumatautipotilailla, kun taas plasman sRAGE-
pitoisuudet olivat vähentyneet tupakoitsijoilla ja tupakoivilla keuhkoahtaumatautipotilailla. 
Molempien biomarkkerien pitoisuudet olivat yhteydessä ajan myötä heikkenevään ilmateiden 
ahtaumaan tupakoivilla keuhkoahtaumatautipotilailla. Yskösnäytteiden NGAL:n pitoisuuksien 
perusteella voitiin erotella ACOS-potilaat keuhkoahtaumatautipotilaista ja NGAL:n 
pitoisuudet myös liittyivät ilmateiden ahtauman vaikeusasteeseen (FEV1% viitearvo). 
 
 
Yhteenvetona TGM2 on mahdollinen biomarkkeri keuhkoahtaumataudin vaikeusasteeseen 
liittyvään diagnostiikkaan. BPIFB1- ja sRAGE -proteiineilla on tärkeä merkitys tupakoinnista 
aiheutuvassa keuhkoahtaumataudissa. Keuhkoahtaumatauti- ja ACOS-potilailla on erilaiset 
yskösten NGAL:n pitoisuudet. Tutkimamme biomarkkerit ovat lupaavia uusia biomarkkereita 
keuhkoahtaumataudin diagnostiikkaa ja hoitoa varten. Lisäksi niistä voisi olla hyötyä astman, 
keuhkoahtaumataudin ja ACOS:n välisessä erotusdiagnostiikassa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
By 2020, chronic obstructive pulmonary disease (COPD) is projected to be the 3rd leading 
cause of death in the world (Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
2017).  According to the World Health Organization (WHO) report, approximately 3 million 
people in the world die as a consequence of COPD yearly (Diaz-Guzman et al. 2014). COPD 
is a common, preventable and treatable disease characterized by persistent respiratory 
symptoms and airflow limitation (GOLD 2017). It is a heterogeneous disease with multiple 
phenotypes (Naz et al.2017), thus different COPD phenotypes could be associated with 
different clinical features, prognostic and therapeutic ramifications. Asthma-COPD overlap 
syndrome (ACOS) is known as a consensus-based clinical phenotype and the patients share 
features common to both asthma and COPD (Gao et al. 2016, Global Initiative for Asthma 
(GINA) 2016, GOLD 2017). The public health efforts aimed to better understand and prevent 
the burden of COPD (Diaz-Guzman et al. 2014), but under-recognition (especially in early 
disease stages) and under-diagnosis (due to overlap with other diseases) in COPD are still very 
common (GOLD 2017, Capozzolo et al. 2017, Adeloye et al. 2015). Early-stage COPD is 
challenging to diagnose, because the patients with mild-moderate COPD may have early 
changes in systemic inflammation, pathology and physiology, but the patient may not have 
significant clinical symptoms (Hogg et al. 2004, Rodriguez-Roisin et al. 2009, Agusti et al. 
2012).  ACOS patients experience poorer outcomes than those with asthma or COPD alone 
(GINA 2016, GOLD 2017), but the pathophysiological features of ACOS are poorly 
understood (Iwamoto et al. 2014).   
 
Air pollution, chronic bronchitis, infections, biomass smoke and dietary factors are important 
risk factors for COPD (Rosenberg et al. 2015, Diaz-Guzman et al. 2014, GOLD 2017). 
Cigarette smoking remains the one of the main risk factors for chronic airway diseases (CAD). 
Smoking is associated with COPD, increased asthma severity and with accelerated lung 
function decline in both current and former smokers (Vonk et al. 2017, GOLD 2017, Nakamura 
et al. 2009, Eisner et al. 2007). Therefore, smoking cessation has the great capacity to influence 
lung function trajectory and progression of COPD (GOLD 2017), and also plays the roles in 
asthma (GINA 2017). Nicotine replacement therapy and other medications (e.g. varenicline, 
bupropion and nortriptyline) are used as a component in the prevention and treatment for 
COPD (GOLD 2017). It has reported that long-term quitting success rates of up to 25% can be 
achieved if effective resources and time are dedicated (van Eerd et al. 2016). The history of 
severe childhood respiratory infection could be a risk factor for COPD, which is associated 
with declined lung function and increased respiratory symptoms in adulthood (de Marco et al. 
2011). In addition, HIV infection and tuberculosis has been identified as the risk factor for 
COPD (Drummond et al. 2014, Byrne et al. 2015). 
 
 
 
The patients with COPD commonly have the declined exercise tolerance on the basis of the 
symptoms, such as dyspnoea (Katajisto et al. 2017).  Pulmonary rehabilitation is based on 
exercising, which has been proven to effectively influence the prevention and maintenance 
therapy in COPD (GOLD 2017). It improves symptoms, quality of life, and physical emotional 
participation in daily activities (GOLD 2017). The pharmacologic therapy is widen used for 
COPD, which could contribute to reducing symptoms, frequency and severity of exacerbation 
and improving health status and physical activity (GOLD 2017), but the role of pharmacologic 
therapy was limited in COPD development and progression, especially in modifying lung 
function decline (GOLD 2017, Burge et al. 2000, Anthonisen et al. 1994, Pauwels et al. 1999, 
Vestbo et al.1999). 
 
Spirometry provides an objective measurement of the presence of airflow limitation, and the 
level of forced expiratory volume in 1 second (FEV1) has been recognised as an important 
value to reflect COPD staging (GOLD 2017, Pellegrino et al. 2005, Naz et al. 2017), but 
spirometry cannot explain a wide variety of COPD phenotypes. The diagnosis of COPD is 
based on a post-bronchodilator fixed FEV1 / forced vital capacity (FVC) ratio <70 %, the 
presence of symptoms (Segreti et al. 2014) and the risk factors (GOLD 2017). Since the 
research by Lange (Lange et al. 2015), at least two trajectories showed in the development of 
airflow limitation, including the trajectory of rapid decline in FEV1 from a normal pulmonary 
function and the trajectory of normal decline in FEV1 from a low FEV1 in initial. Meanwhile, 
the level of lung function in early adulthood may be strongly associated with the diagnosis of 
COPD later in life (Lange et al. 2015). Therefore, early diagnosis has a dominant role in 
improving prognosis or outcomes in COPD. Accordingly, considering the disease 
heterogeneity and lack of predictive molecular markers (Naz et al. 2017), identification of 
sensitive and specific biomarkers is needed to differentiate the multiple COPD phenotypes. 
These biomarkers could also improve both prevention and understanding of the disease and 
optimise patient classification for development of precision medicine in COPD.  In this thesis, 
we investigated potential novel biomarkers for clinical COPD phenotypes in sputum, plasma 
and lung tissue. The studies included two projects and five studies. These projects were the 
early diagnosis of COPD project (Study I, II and III), which used a 6-year longitudinal cohort 
of adult smokers, and the characterisation of ACOS project (Study IV and V), which used a 
Finnish discovery cohort and a Japanese replication cohort. 
 
In the early diagnosis of COPD project (Study I, II and III), we investigated over 80 proteins 
for COPD by non-hypothesis-based proteomic approaches to investigate the roles of potential 
biomarkers in COPD development using the 6-year longitudinal cohort of adult smokers. We 
identified three potential biomarkers for COPD specificity: transglutaminase 2 (TGM2, Study 
I), bactericidal/permeability-increasing (BPI) fold-containing protein B1 (BPIFB1, Study II) 
and soluble receptor for advanced glycation end-products (sRAGE, Study III). TGM2 is a 
 
 
multifunctional enzyme (Lai et al. 2013) and its levels are elevated in the airways (Hallstrand 
et al. 2010, Maiuri  et al. 2008, Witsch  et al. 2014). BPIFB1 is localised in airway goblet cells 
(Bingle et al. 2010, Bingle et al. 2011 (1) 2005 (2)), and sputum BPIFB1 levels are elevated in 
smokers and in COPD (Ohlmeier et al. 2012). sRAGE is expressed in type I pneumocytes 
(Iwamoto et al. 2014) and is a pneumocyte-derived biomarker. Plasma sRAGE levels are 
significantly declined in COPD and accelerated decline is observed in exacerbation stage 
(Smith et al. 2011, Miniati et al. 2011, Sukkar et al. 2012). The present project investigated the 
biomarkers in different samples, using lung tissue (Study I and II), sputum (Study I, II and III) 
and plasma (Study I and III). 
 
In the ACOS project (Study IV and V), we first investigated the four COPD-related biomarkers 
in sputum and plasma (Study IV), namely neutrophil gelatinase-associated lipocalin (NGAL), 
myeloperoxidase (MPO), surfactant protein A (SP-A) and sRAGE in the Finnish discovery 
cohort. In the further study (Study V), we subsequently assessed the COPD biomarkers (NGAL 
and MPO) and added the asthma-related biomarkers (interleukin (IL)-13) and other potential 
biomarkers (chitinase-like protein YKL-40 (YKL-40) and IL-6) in sputum, which were 
analysed in the Finnish discovery cohort and the Japanese replication cohort. NGAL and MPO 
are known as COPD-related biomarkers, which represent neutrophil inflammation and early 
airway injury (Iwamoto et al. 2014, Keatings et al. 1997). SP-A and sRAGE are pneumocyte-
related biomarkers. SP-A is one of the critical markers in lung host defence related to tobacco 
use (Ilumets et al. 2011, Mazur et al. 2011, Ohlmeier et al. 2008). sRAGE is an alveolar type I 
(AT I) cell injury biomarker. IL-13 is a type 2 T helper cells (Th2) marker and is associated 
with asthmatic inflammation (Dente et al. 2012, Wills-Karp et al. 1998). YKL-40 is secreted 
by neutrophils (Volck et al. 1998) and is related to chronic airway inflammation (Tang et al. 
2010, Otsuka et al. 2012, James et al. 2016). IL-6 is a pro-inflammatory cytokine (Schmidt-
Arras et al. 2016) and is associated with impaired lung function (Fu et al. 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF THE LITERATURE  
 
1. Definition of COPD and pathogenesis of COPD  
 
1.1. Definition of COPD 
As noted in the 2017 update of GOLD strategy, the definition of COPD is a common, 
preventable and treatable disease which is characterised by persistent airflow limitation and 
with an enhanced chronic inflammatory response in the airways and the lungs to noxious 
particles or gases. Chronic bronchitis and emphysema are known clinical characteristics of 
COPD (Wright et al. 2008, Roggli et al. 2008). Chronic bronchitis is defined as a productive 
cough of over three months for more than two successive years in general (Barnes et al. 2003) 
and may be an independent disease entity correlated with development or acceleration (or both) 
of fixed airflow limitation (GOLD 2017).  
 
The GOLD 2017 strategy highlights the COPD phenotypes and considers the roles of patient 
symptoms and exacerbation risks in individualised therapeutic decision-making and care 
(Tudoric et al. 2017). COPD may result in emphysema and small airway fibrosis, further 
leading to characteristic symptoms of COPD such as dyspnoea, cough and/or sputum 
production (GOLD 2017, Salvi et al. 2009). These symptoms, however, may be under-reported 
(GOLD 2017). The characteristic features of COPD include a mixture of small airways disease 
and parenchymal destruction, such as obstructive bronchiolitis and emphysema. Those features 
include airway inflammation, airway fibrosis, luminal plugs, increased airway resistance, loss 
of alveolar attachments and decrease of elastic recoil (GOLD 2017). Tobacco smoking remains 
the main risk factor in COPD, whereas host factors (genetic abnormalities, abnormal lung 
development and accelerated aging) may also play crucial roles in COPD development (GOLD 
2017, Stern et al. 2007, McCloskey et al. 2001, Rennard et al. 2006, Stoller et al. 2005, 
Hunninghake et al. 2009, Lawlor et al. 2005). COPD exacerbations lead to acute worsening of 
respiratory symptoms (GOLD 2017, Hurst et al. 2007, Wedzicha et al. 2007, Seemungal et 
al.1998, Burge et al. 2003), which is associated with rapid disease development.  Additionally, 
comorbidities occur frequently in patients with COPD (GOLD 2017, Chen et al. 2015, Brenner 
et al. 2012, Fry et al. 2012). 
 
1.2. Pathogenesis of COPD 
The pathological changes characteristic of COPD includes chronic lung inflammation and 
structural changes caused by repeated injury and repair located in the airways, lung 
parenchyma and pulmonary vasculature (Hogg et al. 2004). According to the GOLD strategy 
2017, COPD pathogenesis is associated with oxidative stress (Barnes et al. 2016, Domej et al. 
2014), protease-antiprotease imbalance (Stockley et al.1999, Johnson et al. 2015), 
inflammatory cells (Barnes et al. 2016), inflammatory mediators (Barnes et al. 2014), 
 
 
peribronchiolar and interstitial fibrosis (Sze et al. 2015, Churg et al. 2006) and so on. It has 
been shown that smoking-induced systemic inflammation and oxidative stress are the major 
risk factors for COPD, and this inflammation persists after smoking cessation (Cosio et al. 
2009). Inhaled cigarette smoke and other noxious particles are chronic irritants, leading to 
chronic inflammation in the airway. This chronic inflammation with increased presence of 
specific inflammatory cell types may be further amplified by oxidative stress (Rahman et al. 
2005).  
 
1.3. Systemic inflammation in COPD 
COPD is mainly characterised by chronic bronchitis, emphysema, or a combination (Martinez 
et al. 2016) and associated with systemic inflammation. COPD involves several types of 
inflammatory cells and a variety of inflammatory mediators (Barnes et al. 2003). Alterations 
in circulating inflammatory cells (e.g. neutrophils and lymphocytes) indicate a downstream 
effect (Sinden et al. 2010). COPD is associated with abnormal inflammatory immune responses 
of the lung to inhaled substances (Brusselle et al. 2011, Sinden et al. 2010), such as cigarette 
smoking, passive smoking, air pollution and occupational exposures (Postma et al. 2015). 
These inhaled substances can enter the circulation and cause systemic inflammation (Sinden et 
al. 2010). Increased number of neutrophils, macrophages and T lymphocytes are found in the 
alveoli and small airways of COPD (Retamales et al. 2001, Forsslund et al. 2017). Neutrophilic 
and CD8 mediated inflammation are considered the main inflammatory players in COPD 
(Martinez et al. 2016). CD8+ cytotoxic T cells (Tc) are the primary T lymphocytes in COPD 
and can destroy lung parenchyma through cytolytic activity. On the other hand,  CD4+ Th cells 
recruit and activate other immune cells, such as neutrophils (Forsslund et al. 2017). COPD is 
associated with several systemic effects (Sinden et al. 2010), such as skeletal muscle 
dysfunction (a statement of American Thoracic Society (ATS)/European Respiratory Society 
(ERS). 1999), cardiovascular disease (Sin et al. 2005), osteoporosis (Bolton et al. 2004) and 
diabetes (Schmidt et al. 1999). Levels of several systemic inflammation-related markers are 
significantly increased in COPD (Sinden et al. 2010), including C-reactive protein (CRP), IL-
6, fibrinogen, activated leukocytes and tumour necrosis factor α (TNFα) (Gan et al. 2004, 
Sinden et al. 2010). The release of multiple inflammatory mediators, such as chemokines, 
cytokines and growth factors is another important feature in COPD (Barnes et al. 2003, GOLD 
2017). Increased inflammatory mediators are associated with the inflammatory process and 
structural changes in COPD (GOLD 2017).  
 
1.4. Major inflammatory cells in COPD  
1.4.1. Neutrophils 
Neutrophils represent nearly 70% of peripheral blood leukocytes (Camicia et al. 2014) and is 
the major inflammatory cell at the site of acute inflammation. Neutrophils play a critical role 
in both controlling infection and in dysregulation of immune responses (Shen et al. 2017). 
 
 
Neutrophils are recruited to the airways and lung parenchyma from the circulation, where the 
recruited neutrophils could rapidly transit through, and neutrophils in COPD airways can be 
further activated (Barnes et al. 2003). The levels of activated neutrophils are increased to 
different degrees in sputum, bronchoalveolar lavage fluid (BALF), airways and lung 
parenchyma (Keatings et al. 1996, Lacoste et al. 1993, Finkelstein et al. 1995). Neutrophils 
secrete serine proteases, which can induce tissue damage leading to alveolar destruction 
(Barnes et al. 2003). Neutrophils can adhere to endothelial cells in the alveolar wall and migrate 
into the respiratory tract (Hogg et al. 1995, Barnes et al. 2003). For example, upregulated E
selectin levels have been found in endothelial cells in COPD (Di Stefano et al. 1994). NGAL 
may be actively secreted by neutrophils (Eagan et al. 2010) and detected in the lungs (Cowland 
et al. 1997). Cigarette smoke may increase the local concentration of neutrophils in the lung 
(MacNee et al. 1989). In smokers, increased neutrophil levels in sputum are correlated with 
reduced lung function (Keatings et al. 1996) and are associated with airflow limitation severity 
in bronchial biopsies (Di Stefano et al. 1998). 
 
1.4.2. Eosinophils 
Eosinophils constitute nearly 1% of the leukocytes in the peripheral blood of humans. 
Eosinophilic inflammation is present in asthma, especially in severe asthma and Th2-high 
asthma (Varricchi et al. 2017). Although the role of eosinophils in COPD is not fully 
understood, the increased levels of eosinophil basic proteins in sputum has been observed in 
COPD (Barnes et al. 2003). Meanwhile, in some patients with COPD, especially with ACOS, 
increased level of eosinophils and Th2 were observed (GOLD 2017). Eosinophils represent 
repositories of some cationic proteins, cytokines, chemokines and lipid mediators (Varricchi et 
al. 2016), and are an important cell type in modulating the functions of a wide spectrum of 
immune cells (Varricchi et al. 2017). Eosinophils can migrate into allergic inflamed tissues and 
subsequently adhere to activated endothelial cells (Furuta et al. 2014). 
 
1.4.3. Differences in inflammatory cells between COPD and Asthma 
Asthma and COPD are different heterogeneous CAD with multiple clinical phenotypes, which 
are associated with differences in physiological effects, symptoms, and response to therapy 
(Fabbri et al. 2003). While asthma and COPD exhibit differences in inflammatory cells and 
mediators, ACOS patients may combine asthma and COPD inflammatory patterns. Eosinophils, 
neutrophils or both in the lung are an important characteristic in asthma patients, whereas 
COPD patients may exhibit systemic inflammation. Severe eosinophilic inflammation-
predominant asthma and persistent airflow limitation may be an important cluster in adult-
onset asthma (Amelink et al. 2013). Neutrophilic inflammation with increased eosinophil 
counts are observed in some COPD (Barnes et al. 2016). ACOS as the intersection between 
asthma and COPD, may have the features of eosinophilic- and neutrophilic-like inflammation. 
 
 
 
2.  Clinical phenotypes in COPD 
 
2.1. Recognized COPD phenotypes on the basis of current evidence 
A phenotype is an observable characteristic obtained from different scales, including the 
interactions between genes and environment (Barker et al. 2013). The clinical COPD 
phenotypes are associated with clinical characteristics, natural history or response to therapy 
(or both) (Burgel et al. 2014). COPD phenotypes can be described at the gene (genomic, 
epigenomic), cell (cellular arrays, proteomics, metabolomics), tissue (histopathology), organ 
(lung function and imaging) and individual (symptoms and signs) (Barker et al. 2013) level. 
Several studies have reported that COPD covers multiple clinical phenotypes with clearly 
different characteristics (Vanfleteren et al. 2016), for example, chronic bronchitis, 
emphysematous and ACOS (Cheng et al. 2017, de Oca et al. 2012, Oh et al. 2014, Gelb et al. 
2016, Izquierdo-Alonso et al. 2013). Those phenotypes of COPD could be with frequent 
exacerbations and with infrequent exacerbations (Cheng et al. 2017). It has been reported that 
approximately 16% the patients with frequent exacerbations have emphysematous (Blasi et al. 
2017). Furthermore, ACOS has been recognized as a predictor for frequent exacerbations in 
COPD (Wan et al. 2011). While chronic bronchitis is an important clinical diagnostic factor in 
COPD and related to airflow limitation development, chronic bronchitis also exists in the 
normal lung function population (GOLD 2017). ACOS is not represent single discrete disease 
entity (Woodruff et al. 2017), defined by shared clinical features from both asthma and COPD, 
particularly in smokers and older adults (GINA 2016, GOLD 2017). ACOS outcomes are often 
poorer than those of asthma or COPD alone. The underlying mechanisms behind different 
ACOS are still not identified (Iwamoto et al. 2014). Recently, ACO has been reconsidered, 
which is without syndrome (Woodruff et al. 2017). It mainly used to describe two types patients, 
such as the asthma patients who have features of COPD and the COPD patients with features 
of asthma (Woodruff  et al. 2017). Hence, distinguishing COPD phenotypes can improve the 
understanding of distinct subgroups, prognostic information and clinical outcome (Barker et al. 
2013, Han et al. 2010). 
 
2.2. Identification of clinical COPD phenotypes with biomarkers 
The Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points 
(ECLIPSE) and Burgel studies confirmed that COPD patients with comparable airflow 
limitation (e.g. FEV1 % predicted) showed marked heterogeneity in clinical characteristics 
(Burgel et al. 2014, Agusti et al. 2010). These subjects belonged to different phenotypes and 
marked differences in clinical characteristics, symptoms, exacerbation rates, exercise capacity, 
comorbidities, predicted mortality and health status (Burgel et al. 2010, 2014). Identifying the 
clinical phenotypes of COPD can contribute to understanding of disease pathophysiology, 
clarifying specific biomarkers and improving the precision, effectiveness and safety of COPD 
patient treatment (Burgel et al. 2014, Agusti et al. 2017). The newest GOLD strategy redefined 
 
the classification of COPD into ABCD groups, based on assessment of symptoms and risk of 
exacerbations. Biomarkers may facilitate defining phenotypes of patients with chronic airway 
diseases (Burgel et al. 2014), which might reflect the pathophysiological mechanism of COPD. 
Apart from biomarkers, other characteristics can also be used to define COPD phenotypes, 
including clinical manifestations and outcomes, imaging, pulmonary function and exercise 
tests (Burgel et al. 2014). It is a challenging to identify COPD-relevant phenotypes and their 
specific biomarkers on the basis of integrating knowledge of bioinformatics, clinical science,
systems biology and network medicine.  
3. Diagnosis of COPD  
3.1. Classification of COPD severity 
In COPD diagnosis, symptom status and risk factors must be evaluated before spirometry. 
Further spirometry is required to establish a diagnosis of COPD (Figure 1). The assessment of 
COPD patient symptoms, severity of spirometric abnormality, exacerbation risk and presence 
of comorbidities may contribute to the classification of COPD severity (GOLD 2017). The 
COPD Assessment Test (CAT) and modified Medical Research Council Dyspnoea Scale 
(mMRC) can evaluate the symptoms and quality of life status in COPD (Jones et al. 2009, 
Kankaanranta et al. 2015, GOLD 2017). The obstruction severity of COPD is assessed based 
on the FEV1 % predicted and FEV1 /FVC (Table 1). In addition, exercise tolerance, level of 
symptoms, exacerbations and co-morbidities are also considered in evaluation of clinical 
COPD severity (Table 1). According to the GOLD 2017 recommendations, COPD can be 
classified into ABCD groups, defined on the basis of symptoms and history of exacerbations 
(Figure 2), this is in contrast with previous GOLD strategy (Tudoric et al. 2017). The 
limitations of the FEV1 affects therapeutic decisions in COPD (GOLD 2017). 
Figure 1: Pathway to diagnosis of COPD with key indicators  
 
Figure 1 is modified from GOLD strategy 2017.  
 
Table 1: Severity of airflow limitation and clinical severity in COPD 
Table 1 is modified from GOLD strategy 2017 and Kankaanranta et al. Basic Clin Pharmacol Toxicol. 2015. *: 
all patients with FEV1 /FVC <0.70; **: at least one condition is fulfilled.  
Figure 2: Assessment ABCD groups in COPD  
 
Figure 2 is modified from GOLD strategy 2017. 
Severity of Airflow Limitation in COPD* 
GOLD Severity FEV1 post-bronchodilator (%, predicted) 
1 Mild  ≥80% 
2 Moderate 50% - 79% 
3 Severe 30% - 49%  
4 Very Severe <30%  
Clinical severity of COPD* 
Type Severity Conditions 
1 Mild CAT <10,  
   no frequent exacerbations and FEV1 >50% predicted 
2 Moderate-Severe** FEV1  <50% predicted 
   At least 2 exacerbations/year OR 1 hospitalisation because of COPD 
   CAT ≥10 OR causes poor quality of life OR impaired exercise tolerance 
3 Very Severe** FEV1 < 30% predicted 
   Chronic respiratory failure 
   Frequent exacerbations OR hospitalisations regardless of treatment to COPD 
   CAT ≥20 OR causes very poor quality of life OR exercise tolerance 
 
 
3.2. Asthma-COPD overlap syndrome (ACOS) 
According to GINA strategy (GINA 2016) and the Finnish Guidelines (Kankaanranta et al. 
2015), ACOS is a phenotype of COPD and is defined by the features that it shares with both 
asthma and COPD (Table 2). ACOS is characterised by persistent (but not fully reversible) 
airflow limitation, often with current or historical variability (GINA 2016). ACOS outcomes 
are often poorer than for asthma or COPD alone, such as lower health-related quality of life 
(HRQoL), faster disease progression, higher morbidity and mortality, increased health care 
utilisation and frequency of exacerbation (de Marco et al.  2013, Kauppi et al. 2011, Louie et 
al. 2013, Miravitlles et al. 2013, Shaya et al. 2008, Soriano et al.2005). ACOS patients often 
have asthma and a history of noxious substance exposure. The age of ACOS onset is usually > 
40 years and is more prevalent in the elderly (Zeki et al. 2011, GINA 2016). The inflammatory 
cells of ACOS are sputum eosinophils, neutrophils or both, suggesting asthma and 
inflammation characteristic of COPD (GINA 2016). As ACOS is a group of heterogeneous 
diseases with multiple phenotypes, defining ACOS remains challenging. Several studies have 
reported the partial characterisation of ACOS based on clinical features and pathophysiological 
and genetic identifiers (Hardin et al. 2011, Carolan et al. 2013, Wardlaw et al. 2005). However, 
further research is needed to understand the mechanisms of ACOS in broad population. 
Diagnostic confusion between COPD, asthma and ACOS is common based on spirometry, 
clinical data and symptoms (Rogliani et al. 2016, Silva et al. 2004, Zeki et al. 2011), 
particularly in distinguishing between asthma with fixed airflow obstruction, COPD and ACOS 
(GINA 2016). Overall, ACOS is a group of consensus-based clinical diseases with different 
characteristics, consisting of several phenotypes (Rogliani et al. 2016). Although guidelines 
for ACOS are continuously updated, knowledge of the disease is still limited, particularly in 
smokers and older adults. As a heterogenic disease with poorly defined clinical features, it is a 
challenging to diagnosis ACOS (Tommola et al. 2017). Novel biomarkers may facilitate 
identification of the similarities and differences in asthma, COPD and ACOS. Such biomarkers 
may also be useful in clarifying the clinical phenotype (Iwamoto et al. 2014, Gao et al. 2016). 
 
4. Epidemiology and aetiology of COPD  
 
Globally, COPD is the one of the main diseases causing disability, illness and death (Machin 
et al. 2017, GOLD 2017). The number of COPD cases increased to approximately 390 million 
in 2010 globally (Adeloye et al. 2015). The prevalence and burden of COPD are high and 
growing both globally and regionally. However, it is challenging to accurately assess COPD 
prevalence due to differences in research methods and diagnostic criteria (Halbert et al. 2006). 
COPD prevalence ranged from 8.4 -15.0% in 2010 (Adeloye et al. 2015, Machin et al.2017). 
In general, the prevalence of COPD is less than 6% in most countries (GOLD 2017). COPD 
prevalence is nearly 50% in heavy smokers (Rennard et al. 2006). Age and cigarette smoking  
 
 
 
Table 2: Features of asthma, COPD and ACOS 
 
Feature Asthma COPD ACOS 
Age of onset (usually) Childhood >40 years >40 years  
Pattern of respiratory 
symptoms 
Vary over time  Chronic Persistent exertional dyspnoea  
Often limiting activity Continuous symptoms Variability may be prominent 
Often triggered by exercise, 
emotions 
    
Airflow limitation Variable Persistent Not fully reversible 
History Frequently a history of allergies in 
childhood 
Exposure to noxious particles 
and gases  
Frequently a history of doctor-
diagnosed asthma 
Frequently a personal history of 
asthma in childhood 
Frequently a history of allergies 
May have family history of asthma Frequently a family history of 
asthma 
 May have a history of noxious 
exposures 
Time course  Often improves spontaneously  Slowly progressive Reduced symptoms by treatment 
May result in fixed airflow 
limitation 
  Usual progression  
    High-level treatment 
Chest X-ray Usually normal Severe hyperinflation  Similar to COPD 
Other changes of COPD 
Exacerbations Considerably reduced by treatment Considerably reduced by 
treatment 
May be more common than in 
COPD 
Risk can be considerably reduced 
by treatment 
Reduced by treatment 
Airway inflammation Eosinophils, neutrophils or both Neutrophils ± eosinophils in 
sputum  
Eosinophils, neutrophils or both 
in sputum 
Lymphocytes in airways 
May have systemic 
inflammation 
Spirometry       
Post-BD*  
FEV1 FVC <0.7 
May improve spontaneously or on 
treatment  
Required for diagnosis Usually present 
FEV1 ≥80% predicted Compatible with diagnosis Compatible with GOLD mild 
stage 
Compatible with mild ACOS 
FEV1 <80% predicted Compatible with diagnosis Severity of airflow limitation Severity of airflow limitation 
Risk factor for exacerbations Risk of future events Risk of future events 
Post-BD* increase in 
FEV1 >12% and 200 ml 
from baseline 
Usual  Usual Usual 
Post-BD* increase in 
FEV1 >12% and 400 ml 
from baseline 
High probability of asthma  Unusual in COPD Compatible 
Consider ACOS 
 
Table 2 is modified from GINA strategy 2016. * post-BD: post-bronchodilator spirometry. 
 
 
are well-known major risk factors in COPD (Jyrki-Tapani et al. 2005, Lokke et al. 2006, 
Mannino et al. 2007, Lindberg et al. 2006, Shahab et al. 2006) and have a synergistic effect 
(Lindberg et al. 2006). Moreover, advanced age and smoking history are also considered as 
clinical characteristics in ACOS (GINA 2016). An early smoking starting age is a strong risk 
factor for COPD (Jyrki-Tapani et al. 2005). Recently, Lopez-Campos and co-workers reported 
that the standardised mortality of COPD has declined in Western countries, based on the 
development of smoking cessation tools and other anti-smoking efforts (Lopez-Campos et al. 
2016). Nevertheless, COPD prevalence is still high due to the impact of aging and the 
increasing of air pollution and regional smoking. Tuberculosis history and exposure to biomass 
are other known risk factors for COPD (Amaral et al. 2015, Hooper et al. 2012, Rivera et al. 
2008). In addition, several studies reported that never smokers may account for approximately 
30% of patients with COPD (Celli et al. 2005, Behrendt et al. 2005, Lamprecht et al. 2008, 
Bridevaux et al. 2010). Altogether, COPD still is a challenge for clinicians and for social 
healthcare worldwide. 
 
5. Effect of smoking in the airway in COPD  
 
COPD is recognised as a smoking-related lung disorder, but not all smokers develop COPD. 
Susceptible smokers may easily develop irreversible lung obstruction (Fletcher et al. 1977, 
Faner et al. 2014), which is associated with their genetic and epigenetic background (Vestbo 
et al. 2013, Lomas et al. 2001, Silverman et al. 2000, DeMeo et al. 2004). Small airway (<2 
mm in diameter) remodelling is the major factor leading to airflow obstruction (McDonough 
et al. 2011). COPD with progressive irreversible airway obstruction is associated with 
smoking-induced changes in the small airways, and smoking-induced pathological changes 
play an important role in COPD development (Hogg et al. 2004). Hogg study reported that 
exposure to tobacco smoke leads to thickened small airway epithelium and increased occlusion 
of small airways by mucus, which may lead to airway remodelling and further airway 
obstruction (Hogg et al. 2004). Smoking behaviour is associated with multiple factors and their 
interactions, including genetic, social and psychological factors. Tobacco-related deaths 
account for a large proportion of preventable deaths in the world, such as COPD (Rigotti 2013). 
It is recommended that clinicians encourage smoking cessation in smokers (Wu et al. 2006). 
Importantly, the GOLD 2016 guideline emphasised that smoking cessation is the key 
intervention in COPD, based on strong (type A) evidence. Meanwhile, Fletcher study reported 
that smoking cessation could revert the average further rates of FEV1 loss to normal in 
susceptible smokers (Fletcher et al. 1977).  
 
 
 
 
 
 
6. Treatment strategies for COPD  
 
6.1. Smoking cessation 
Smoking cessation is in central role to avoid COPD.  While relapse is common in patients that 
stop smoking, the ‘5 A’ program (Ask, Advise, Assess, Assist and Arrange) provides a strategic 
framework for smoking cessation. Nicotine replacement products are an important part of this 
program (GOLD 2017, Glynn et al.1990), which have different types of in market, including 
nicotine gum, inhaler, nasal spray, transdermal patch, sublinual tablet, and lozenge (GOLD 
2017). Nicotine replacement therapy has been proved to reliably increases long-term smoking 
abstinence rates (GOLD 2017, the Tobacco Use and Dependence Clinical Practice Guideline 
Panel. 2000, van der Meer et al. 2003). E-cigarettes are popularly used, but the efficacy still is 
controversial (GOLD 2017, McNeill et al. 2015, McRobbie et al. 2014). There are several other 
pharmacological products for smoking cessation, that would be used as a component of a 
supportive intervention program, such as varenicline, bupropion and nortriptyline (GOLD 
2017, Cahill et al. 2013, Tashkin et al. 2011(1) (2)). 
 
6.2. Pulmonary rehabilitation therapy 
Pulmonary rehabilitation therapy is an important method in the integrated care of the patient 
with chronic respiratory disease. As the note of the 2013 updated official ATS/ERS statement 
(Spruit et al. 2013), pulmonary rehabilitation has been defined as “a comprehensive 
intervention based on a thorough patient assessment followed by patient-tailored therapies, 
which include, but are not limited to, exercise training, education, and behavior change, 
designed to improve the physical and psychological condition of people with chronic 
respiratory disease and to promote the long-term adherence of health-enhancing behaviors.” 
Pulmonary rehabilitation may be used for increasing exercise capacity (Lacasse et al. 2002, 
GOLD 2017), which is efficient when measured by saved hospital days in severe COPD 
(Katajisto et al. 2017). Meanwhile, new pulmonary rehabilitation methods are currently being 
investigated. 
 
6.3. Pharmacologic therapy for stable COPD 
To date, the pharmacologic therapy for stable COPD mainly include bronchodilators, 
antimuscarinic drugs, methylxanthines, combination bronchodilator therapy, anti-
inflammatory agents, inhaled corticosteroids (ICS), triple inhaled therapy, oral glucocorticoids, 
phosphodiesterase-4 inhibitors, antibiotics, mucolytic and antioxidant agent, and other 
pharmacologic treatments (GOLD 2017). Pharmacologic therapy for COPD is to reduce 
symptoms, reduce the frequency and severity of exacerbations, and to improve exercise 
tolerance and health status (GOLD 2017). Comparing combination therapy with monotherapy 
in COPD, combination bronchodilator therapy may increase the degree of bronchodilation with 
a similar safety profile (GOLD 2017, Vogelmeier et al. 2008). The combination 
 
 
ICS/bronchodilator therapy provides better control in moderate-very severe COPD patients 
(GOLD 2017, Calverley et al. 2003(1), 2003(2), 2007, 2011, Mahler et al. 2002, Szafranski et 
al. 2003, Hanania et al. 2003, Doherty et al. 2012, Nannini et al.  2012). According to the 
Finnish COPD guidelines (Kankaanranta et al. 2015), the pharmacotherapy of ACOS includes 
at least ICS+long-acting β2-agonists (LABA) or ICS+LABA+long-acting muscarinic 
antagonist (LAMA). 
 
6.4. Vaccination, oxygen therapy and lung-related surgery for COPD 
Prevention of respiratory infections plays an important role in COPD treatment. Accordingly, 
influenza and pneumococcal vaccination are offered to COPD patients (Wongsurakiat et al. 
2003, 2004, Nichol et al. 1994, Edwards et al. 1994, Jackson et al. 2003, Centers for Disease 
Control and Prevention 2010, Alfageme et al. 2006). Oxygen therapy and lung-related surgery 
assist COPD treatment. Oxygen therapy has been widely used in chronic respiratory failure 
patients, and non-invasive ventilation (NIV) is used in severe COPD patients. In addition, 
invasive COPD treatments, such as lung volume reduction surgery (LVRS), bronchoscopic 
lung volume reduction (BLVR) and lung transplantation may improve patient quality of life 
(Christie et al. 2010, Trulock et al.1997, Naunheim et al. 2006, Sciurba et al. 2010). The further 
research is needed to evaluate the outcomes of these interventions. However, while the existing 
medications for COPD may improve symptoms, health status and exercise ability and reduce 
frequency of exacerbations, they do not modify the long-term decline in lung function (GOLD 
2017, Burge et al. 2000, Anthonisen et al. 1994, Pauwels et al. 1999, Vestbo et al.1999). 
 
7. Prognosis of COPD 
 
COPD is a common, preventable and treatable chronic airway disease. The mortality of COPD 
is close to 5% of all deaths globally in 2015 (www.who.int). According to the GOLD strategy 
2017, the different GOLD grades of COPD (GOLD 1-4) show varying characteristics. This 
classification system is defined in 4 grades (from mild to very severe), and can be a predictor 
for future adverse events. COPD may lead to progressive breathlessness, exacerbations, other 
serious related illnesses and low quality of life (www.who.int, Donaldson et al. 2005, Flattet et 
al. 2017, Miravitlles et al. 2000). Frequent exacerbations requiring hospitalisation are related 
to poor prognosis (Soler-Cataluña et al. 2005). Meanwhile, higher exacerbation rates and high 
CAT scores (scores 10) are factors related to reduced quality of life in COPD (Spencer et al. 
2004, Jones et al. 2011). Baseline lung function and demographic factors are strongly 
associated with COPD outcome (Flattet et al. 2017, www.who.int). Tobacco use, biomass fuel 
exposure and air pollution may contribute to COPD development and may affect COPD 
prognosis. ACOS outcomes are poorer than asthma or COPD alone, such as poor HRQoL, 
rapid disease progression, higher morbidity and mortality, greater exacerbation frequency and 
 
 
social burden (Iwamoto et al. 2014, de Marco et al. 2013, Kauppi et al. 2011, Louie et al. 2013, 
Miravitlles et al. 2013, Shaya et al. 2008, Soriano et al. 2005). 
 
8. Novel biomarkers in early diagnosis of COPD and in characterisation of ACOS 
 
8.1. Biomarkers requirement in early diagnosis of COPD and in characterisation of ACOS 
COPD is not a single disease and includes multiple phenotypes. Identification of the similarities 
and differences of COPD clinical phenotypes is increasingly important, as these phenotypes 
have distinct clinical outcomes and different treatment guidelines. Accurate assessment of 
COPD phenotype contributes to improved diagnosis, treatment, and reduced disease 
progression. Currently, COPD is generally diagnosed by symptoms, spirometry and other tests 
(GOLD 2017). Distinguishing the phenotypes of COPD remains challenging, particularly in 
the early and overlapping stage. Some clinical phenotypes exhibit poor or absent correlation 
with lung function decline. In COPD, symptom aggravation may be earlier than lung function 
decline (Seemungal et al. 2000). Meanwhile, the biological features of ACOS are still poorly 
understood (Gao et al. 2016, Bonten et al. 2016). Based on lung function tests, current imaging 
and physiological testing techniques, it remains challenging to unambiguously distinguish 
ACOS from asthma and COPD (Kauppi et al. 2011, Iwamoto et al. 2014, Hardin et al. 2011, 
Gao et al. 2016). Accordingly, novel biomarker solutions are needed for COPD clinical 
assessment, which could be used to accelerate therapeutic discoveries and to improve the care 
and outcomes (Sin et al. 2015). Cross-sectional and longitudinal research on COPD biomarkers 
is on-going globally, as it is likely that sensitive and specific biomarkers would improve COPD 
clinical assessment (Gao et al. 2016, Sin et al. 2015, Hollander et al. 2017). It is crucial to 
evaluate multipanel biomarkers for COPD, which could not only be used to understand the 
pathophysiological features and phenotypes for COPD, but could also contribute to improved 
early COPD diagnosis and clarified the characterisation of ACOS. These findings may 
ultimately be used for developing precision medicine in COPD.  
 
Several potential biomarkers in sputum and blood have been investigated in COPD in the 
ECLIPSE study, referring to novel cellular, proteomic, genetic, transcriptomic and 
metabolomic biomarkers (Faner et al. 2014). Some of these biomarkers have shown promising 
results in COPD, such as neutrophils (Singh et al. 2010), circulating white blood cells (WBC) 
(Agusti et al. 2012, Hurst et al. 2010, Celli et al. 2012), fibrinogen (Celli et al. 2012, Duvoix 
et al. 2013, Casaburi et al. 2013), clara cell secretory protein-16 (CC16) (Lomas et al. 2008, 
Vestbo et al. 2011 Hanania et al. 2011), surfactant protein D (SP-D) (Hurst et al. 2010, Lomas 
et al. 2009), Pulmonary and activation-regulated chemokine (PARC/CCL-18) (Sin et al. 2011), 
soluble receptor for advanced glycation end-products (sRAGE) (Cheng et al. 2013), 
inflammome (Agusti  et al. 2012, Miller et al. 2013), adipokines (Breyer et al. 2012) and 
Vitamin D (Berg et al. 2013). Although the ECLIPSE study identified a panel of biomarkers 
 
 
that were associated with risks of poor clinical outcome (Faner et al. 2014), the utility of these  
biomarkers were still limited in COPD. Sputum neutrophils may not reflect the 
pathophysiological abnormalities in COPD and its specificity is limited (Faner et al. 2014). 
Circulating WBC counts associated with COPD, but its specificity is limited in COPD (Faner 
et al. 2014, Agusti et al. 2012, Hurst et al. 2010, Celli et al. 2012). Plasma fibrinogen has been 
considered as a robust biomarker in COPD (Faner et al. 2014), which is associated with COPD 
prognosis (Casaburi et al. 2013). However, the clinical utility of fibrinogen is still limited, 
particularly with regards to outcomes and COPD risk factors (Faner et al. 2014). Accordingly, 
further investigations are needed to evaluate new biomarkers and to validate previous results. 
 
8.2. Potential biomarkers for early diagnosis of COPD 
8.2.1. Transglutaminase 2 (TGM2) 
Transglutaminases (TGM) is associated with lung extracellular matrix proteins (ECM) via 
protein modifications and crosslinking. TGM may block lung structure modifications and 
prevent remodelling processes in alveolarisation (Witsch et al. 2014). TGM2 is a 
multifunctional enzyme localised to the developing alveolar septa and is associated with cancer 
and autoimmune, inflammatory and neurodegenerative diseases (Ohlmeier et al 2016, Lai et al. 
2013, Witsch et al. 2014). To the best of our knowledge, there are no studies of TGM2 in 
relation to COPD. Some studies have implicated TGM2 levels in asthma (Hallstrand et al. 
2010), pulmonary fibrosis (Oh et al. 2011, Olsen et al. 2011) and bronchopulmonary dysplasia 
(Witsch et al. 2014). These results suggest that TGM2 may play an important role in chronic 
inflammatory diseases (Maiuri et al. 2008), and could contribute to the development of new 
treatments for airway inflammatory diseases. 
 
8.2.2. Bactericidal/permeability-increasing protein fold containing protein B1 (BPIFB1) 
The bactericidal/permeability-increasing fold-containing (BPIF) / palate, lung, and nasal 
epithelium clone (PLUNC) genes are located on a single locus on chromosome 20q11.2 (Bingle 
et al. 2002). Eight of the 11 genes generate functional proteins (Gao et al. 2015). BPIF protein 
B1 (BPIFB1, previously termed long-PLUNC1) is localised in a population of goblet cells in 
the nasal passages and in the airway epithelium. BPIFB1 is also present within the serous cells 
of airway submucosal glands (Bingle et al. 2010, Bingle et al. 2005, 2011). BPIFB1 is strongly 
expressed in the upper respiratory tract (Bingle et al. 2002, Bingle et al. 2007) and may have a 
function in innate defence of the airways (Gao et al. 2015). Elevated BPIFB1 levels have been 
reported in several lung diseases, such as advanced cystic fibrosis (Bingle et al. 2012) and usual 
interstitial pneumonia (Bingle et al. 2013). In addition, our previous proteomics study revealed 
that BPIFB1 levels in sputum were increased in smokers and in COPD (Ohlmeier et al. 2012). 
Therefore, we hypothesised that BPIFB1 is involved in COPD (Gao et al. 2015) and developed 
a functional enzyme-linked immunosorbent assay (ELISA) kit for BPIFB1. 
 
 
 
8.2.3. Soluble receptor for advanced glycation end-products (sRAGE) 
The receptor for advanced glycation end-products (RAGE) is a pattern-recognition receptor for 
an unspecific ligand (Fritz et al. 2011). RAGE belongs to the immunoglobulin superfamily of 
cell-surface receptors (Fritz et al. 2011, Neeper et al. 1992, Schmidt et al. 1992) and participates 
in host response to injury, infection and inflammation (Sukkar et al. 2012). RAGE is associated 
with the inflammatory response and is involved in development of chronic pathologies (Fritz 
et al. 2011), such as chronic inflammation (Hofmann et al.1999) and cancer (Taguchi et al. 
2000). Interesting, RAGE levels differ between those in the lung and in most normal tissues 
(Iwamoto et al. 2014). RAGE levels are lowest in patients with severe COPD in lung tissue 
(Ohlmeier et al. 2010). RAGE is expressed at a high level in AT I cells under normal 
physiological conditions and is associated with lung homeostatic function (Buckley et al. 2010, 
Demling et al. 2006). Soluble RAGE (sRAGE) is known as an AT I cell injury biomarker 
(Buckley et al. 2010) and has anti-inflammatory properties (Park et al. 1998, Englert et al. 
2008). Several studies showed that sRAGE is associated with emphysema, reduced diffusion 
capacity and neutrophilic COPD (Sukkar et al. 2012, Miniati et al. 2011, Iwamoto et al. 2014, 
Cheng et al. 2013). 
 
8.3. Potential biomarkers for characterisation of ACOS  
8.3.1. Neutrophil gelatinase-associated lipocalin (NGAL) 
Neutrophil gelatinase-associated lipocalin (NGAL) is an antimicrobial 25-kDa protein that 
belongs to the lipocalin superfamily (Flower et al. 2000). NGAL covalently binds to gelatinase 
from human neutrophils (Eagan et al. 2010, Mishra et al. 2003). NGAL is actively secreted by 
neutrophils, epithelial cells and tubular cells in the kidneys (Kjeldsen et al. 1994, Eagan et al. 
2010, Nielsen et al. 1996, Bu et al. 2006, Mishra et al. 2003) and may be detected in the lungs, 
stomach, colon and kidney (Cowland et al. 1997). The study by Bolignano reported that NGAL 
levels reflect tubular cell injury and correlate with renal impairment severity (Bolignano et al. 
2008). Increased NGAL levels in COPD patients have been detected in sputum, bronchial 
lavage and plasma (Keatings et al. 1997, Eagan et al. 2010, Ekberg-Jansson et al. 2001). NGAL 
inhibits of bacterial growth and enhances matrix degradation, which may be associated with 
early airway injury in smoking-related diseases and involved in COPD pathogenesis (Keatings 
et al. 1997, Kjeldsen et al. 1994, Eagan et al. 2010). NGAL has a high affinity for siderophores, 
which helps reduce available iron and inhibit bacterial infection by binding to siderophores 
secreted by bacteria (Fischbach et al. 2006, Flo et al. 2004). NGAL inhibits matrix 
metalloprotease 9 (MMP-9) inactivation, which contributes to prolonged effects on collagen 
degradation (Gupta et al. 2007, Yan et al. 2001). These effects suggest that NGAL may be a 
potential mediator in acute and chronic respiratory infections and in protease-antiprotease 
imbalance in COPD (Kjeldsen et al. 1994, Eagan et al. 2010, Fischbach et al. 2006, Flo et al. 
2004). 
 
 
 
8.3.2. Myeloperoxidase (MPO) 
Myeloperoxidase (MPO) is a heme-containing peroxidase and a mediator of neutrophil activity 
(Zhu et al. 2014). MPO is released from secondary granules following neutrophil activation 
(van der Veen et al. 2009, Zhu et al. 2014, Klebanoff. 2005). MPO not only affects with the 
oxidative properties, but also correlates with the processes involved in cell signaling and cell-
cell interactions (Van der Veen et al. 2009). Excessive generation of oxidants by MPO is not 
beneficial in the immune response and may result in host tissue damage associated with acute 
or chronic inflammatory diseases. (Zhu et al. 2014). Elevated MPO levels have been reported 
in asbestos-induced lung impairment (Haegens et al. 2005) and in COPD (Keatings et al. 1997, 
Yamamoto et al. 1997). 
 
8.3.3. Surfactant protein A (SP-A)  
Alveolar epithelium repair is involved in the maintenance of lung homeostasis (Nathan et al. 
2016). Pulmonary surfactant proteins are significant molecular components in host defence and 
in inflammatory regulation in the lung (Nathan et al. 2016, Whitsett. et al. 2005). In particular, 
surfactant protein A (SP-A) plays a critical role in pulmonary defence against inflammation 
and oxidative stress (Whitsett et al. 2005). SP-A is a highly ordered, collagen-like glycoprotein 
and a member of the collectin family. Collectins include a calcium-dependent phospholipid-
binding protein and the lectins (Thiel et al. 1989, Sastry et al. 1993, McCormack. 2001). SP-A 
is secreted primarily by alveolar type II and clara cells, and binds to specific cell surface 
receptors in the lung (Pison et al. 1992, Wright et al. 1989). SP-A affects surfactant structure 
and function and regulates various microbial species (McCormack. 1998 and 2001, LeVine. et 
al. 2000). In our previous proteomics studies, we revealed that SP-A is associated with 
smoking-related lung injury (Ilumets et al. 2011, Mazur et al. 2011, Ohlmeier et al. 2008), and 
that SP-A levels are elevated in plasma and sputum samples from smokers (Mazur et al. 2011). 
Increased SP-A levels have been detected in serum (Behera et al. 2005, Kobayashi et al.  2008, 
Robin et al. 2002) and lung tissue samples (Ohlmeier et al. 2008) from COPD patients. 
 
8.3.4. Chitinase-like protein YKL-40 (YKL-40) 
Chitinase-like protein YKL-40, YKL-40 is for short, which also called human cartilage 
glycoprotein 39 (HCgp-39) and chitinase 3-like 1, encoded by the chitinase 3–like 1 gene 
CHI3L1 (Chupp et al. 2007, Ober et al. 2008). The chitinase family consists of YKL-40, 
chitotriosidase and mammalian chitinase; the levels of these proteins are associated with airway 
inflammation (Lee et al. 2011). YKL-40 binds expressed chitin without the enzymatically 
active, which lacks of chitinase activity (Chupp et al. 2007, Lee et al. 2011, James et al. 2016, 
Ober et al. 2008). YKL-40 has several important roles, such as inhibiting oxidant-induced lung 
injury, augmenting adaptive Th2 immunity, regulating apoptosis, stimulating alternative 
macrophage activation and improving fibrosis and wound healing (Lee et al. 2011). Elevated 
YKL-40 levels were observed in serum of patients with asthma and COPD (Tang et al. 2010, 
 
 
Otsuka et al. 2012, James et al. 2016, Chupp et al. 2007). Serum YKL-40 levels in COPD are 
higher than those in asthma (Chupp et al. 2007). YKL-40 levels are associated with asthma 
severity, airway obstruction and airway remodelling (Bargagli et al. 2010, Chupp et al. 2007, 
Ober et al. 2008). The -131 C/G polymorphism in the CHI3L1 gene (rs4950928) is associated 
with increased serum YKL-40 levels (Ober et al. 2008). Some studies have shown that YKL-
40 levels are associated with subepithelial basal membrane thickness in serum and BALF 
(Chupp et al. 2007) and linked to profibrotic factors and inflammatory cells after allergen 
challenge (Gavala et al. 2013). 
 
8.3.5. Interleukin 6 (IL-6) 
Interleukin-6 (IL-6) is a proinflammatory cytokine with multiple functions and is mainly 
synthesised by monocytes, macrophages, T cells, fibroblasts and endothelial cells (Schmidt-
Arras et al. 2016, Attaran et al. 2010). IL-6 is involved in systemic inflammation and may play 
a considerable role in impaired lung function in COPD (He et al. 2009, Karadag et al. 2008, 
Donaldson et al. 2005) and in mild-moderate asthma (Neveu et al. 2010). Several studies have 
reported elevated serum IL-6 levels in COPD (Attaran  et al. 2010) and ACOS (Fu et al. 2014) 
patients. Increased IL-6 levels are associated with airflow limitation (Attaran et al. 2010). Only 
a few studies have investigated the association of IL-6 with respiratory function in asthma 
(Grubek-Jaworska et al. 2012) and ACOS. 
 
8.3.6. Interleukin 13 (IL-13) 
Interleukin-13 (IL-13) is a classical Th2 pneumocyte-derived biomarker and a central mediator 
in allergic asthma (Grubek-Jaworska et al. 2012). IL-13 is associated with eosinophilic 
inflammatory disease (Bel et al. 2017). IL-13 is involved in multiple roles in the airway, such 
as eosinophil recruitment and retention and regulation of airway hyperresponsiveness (Bel et 
al. 2017).  A panel of anti-IL-13 could improve airway inflammation mediated by eosinophils 
(Bel et al. 2017). Thus far, two monoclonal antibodies against IL-13 (lebrikizumab and 
tralokinumab) have been developed. Based on phase III trial results, lebrikizumab may be 
effective in reducing the rate of exacerbations in uncontrolled asthmatics with moderate to 
severe disease (Hanania et al. 2015, Bel et al. 2017) 
 
9. Proteomics study  
 
Proteomics is a non-biased large-scale screening technique, which is an important method for 
investigating COPD pathology (Ohlmeier et al. 2016). We have investigated the pathological 
mechanisms of COPD using proteomics for many years (Ohlmeier et al. 2008, 2010). Based 
on our proteomic smoking-related and COPD-related studies, a variety of promising molecular 
markers have been reported. These include SP-A (Ohlmeier et al. 2008), RAGE (Ohlmeier et 
al. 2008, 2010), polymeric immunoglobulin receptor (PIGR) (Ohlmeier et al. 2012), α-1-
 
 
antitrypsin (SERPINA1) and BPIFB1 (Ohlmeier et al. 2012). In this thesis, we selected SP-A, 
sRAGE and BPIFB on the basis of our proteomic study. However, further COPD research is 
needed via other methods, as proteomics do not verify the specificity of the identified changes 
(Ohlmeier et al. 2008). Therefore, our selected biomarkers were further measured by 
quantitative ELISA after our proteomic studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDIES 
 
In general, the aim of the studies was to identify COPD-related proteomic involved COPD 
development. Another goal was to identify novel biomarkers for the clinical phenotypes of 
COPD. Finally, we aimed to investigate whether the levels of these markers are associated with 
clinical variables. 
 
The specific aims of my thesis in each study were: 
Study I: to identify COPD-specific proteomic changes involved in disease onset and severity 
in non-smokers, smokers, smokers with mild to moderate (stage I-II) COPD, severe to very 
severe COPD (stage III-IV) and patients with α-1-antitrypsin deficiency (AATD) and 
idiopathic pulmonary fibrosis (IPF). 
 
Study II: to evaluate sputum BPIFB1 levels in smokers and in COPD in a longitudinal study, 
and further to investigate the association of sputum BPIFB1 levels with smoking and 
longitudinal changes in lung function. 
 
Study III: to evaluate the association of plasma sRAGE levels with a longitudinal decline of 
lung function. 
 
Study IV: to clarify the similarities and differences between ACOS and COPD or asthma in 
SP-A, sRAGE, MPO and NGAL levels in sputum and plasma.  
 
Study V: to clarify the inflammatory mediators typical for ACOS, namely five sputum 
biomarkers (IL-13, MPO, NGAL YKL-40 and IL-6) in a Finnish discovery cohort and to 
validate these results in a Japanese replication cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
1. Projects  
 
This thesis work contained the two projects, including the project of early diagnosis of COPD 
in cross-sectional and longitudinal studies (Study I, II and III) and the project of ACOS in 
cross-sectional studies (Study IV and V). The studies were approved by the Ethics Committees 
Helsinki University Hospital (HUH) and Lapland Central Hospital and conducted in 
accordance with the ethical standards established in the Helsinki Declaration of 1975 and Dnro 
125/E0/2004. All participants provided written informed consent. 
 
2. Cohorts 
 
2.1. Main cohorts for sputum and plasma samples 
2.1.1. The 6-year longitudinal cohort of adult smokers for early diagnosis of COPD studies 
(Study I, II and III) 
Induced sputum and plasma samples were collected from the 6-year longitudinal cohort of 
adult smokers (Rovaniemi cohort, Finland) (Toljamo et al. 2015). These participants were 
recruited though newspaper announcements (Toljamo et al. 2015). This longitudinal study 
included three visits (visit 1, visit 2 after two or three years and visit 3 after six years). All visits 
consisted of a personal interview, and all the assessments were conducted by the same 
experienced nurse during the three visits (Toljamo et al. 2015). Based on a detailed self-
reported questionnaire, all participants felt healthy without any chronic diseases and were 
symptom-free at visit 1. Sputum samples, plasma samples and spirometric data were collected 
at visits 2 and 3 (Toljamo et al. 2010, 2015). Therefore, we used visit 2 as baseline and visit 3 
as follow-up in our studies (Iwamoto et al. 2014, Mazur et al. 2011). From 2007 to 2008 (visit 
2, baseline), spirometric measurements and samples were obtained from 345 participants 
(Iwamoto et al. 2014). From 2011 to 2012 (visit 3, 4-year follow-up), there were 295 
participants with a baseline blood sample as well as baseline spirometry and follow-up 
spirometry (Iwamoto et al. 2014). Sputum samples were required to fulfil selection criteria 
(less than 70% squamous epithelial cells), 252 participants fulfilled the criteria and enrolled in 
our studies. The participants had no history of chronic pulmonary diseases, allergies, 
medications, the risk factors for other pulmonary diseases or lung infections during the 2 
months prior to entering the study. COPD patients fulfilled the GOLD criteria for obstruction 
(FEV1/FVC < 0.7); severity was distinguished by using the bronchodilator FEV1 value. In 
addition, the lung tissue samples were retrieved from the patients at HUH (Ishikawa et al. 2010, 
Ohlmeier et al. 2012). COPD, IPF and AATD tissues were obtained from lung transplantations, 
and control tissues were obtained from lung surgery from hamartomas or from the surgery for 
local tumors (Gao et al. 2015, Ohlmeier et al. 2016). The control plasma and sputum samples 
 
 
were obtained from the non-smokers if they were healthy, middle-aged (>40 years), not taking 
any medications, and had normal lung function. 
 
2.1.2. The Finnish discovery cohort and the Japanese replication cohort for ACOS studies 
(Study IV and V) 
Induced sputum and plasma samples were collected from the Finnish discovery cohort, (part 
of the longitudinally followed cohort of Finnish asthma and COPD patients, or FinnCAD Study) 
(Kauppi et al. 2011, Laitinen et al. 2009) and the replication cross-sectional cohort (Hiroshima 
cohort, Japan) (Ishikawa et al. 2015) for ACOS studies. Based on medical history and self-
reported questionnaire data, the study subjects were categorised into five groups in the 
discovery and replication cohort: healthy non-smokers (NS, n=26 and n=22), asymptomatic 
healthy smokers with normal lung function (HS, n=23 and n=40) and patients with asthma 
(Asthma, n=32 and n=21), COPD (COPD, n=39 and n=35) and ACOS (ACOS, n=14 and n=17).  
 
In the discovery cohort, asthma diagnosis was based on the two criteria according to the British 
Guidelines on Asthma Management (British Thoracic Society Scottish Intercollegiate 
Guidelines Network. 2008). The first one indicates that the subjects should fulfil one or more 
of the following findings, including a post-bronchodilator increase in FEV1 of 12%, a 
bronchodilator response of 15% or diurnal variation of 20% in peak expiratory flow (PEF) 
recording, moderate-to-severe bronchial hyper-reactivity or a decrease in FEV1 of 15% in 
the exercise test. The second one is a clinical history compatible with asthma. COPD diagnosis 
in the discovery cohort was based on ATS/ ERS Task Force recommendations (Laitinen et al. 
2009). Specifically, COPD was diagnosed if FEV1/FVC <0.7 or FEV1/FVC <88% predicted 
was in post-bronchodilation spirometry related to long-term smoking (Viljanen et al. 1982, 
Rabe et al. 2007). In the replication cohort, specialists in respiratory medicine diagnosed 
asthma according to GINA strategy (Reddel et al. 2015). COPD patients had airway obstruction 
with a pre-bronchodilator FEV1/FVC < 0.7 (Vestbo et al. 2013, Ishikawa et al. 2015, Viljanen 
et al. 1982) and over 10 pack-years long-term smoking. ACOS was diagnosed if patients 
fulfilled both diagnostic criteria for asthma and COPD. Controls were recruited at HUH 
through hospital and local media announcements, and were never-smokers or current smokers 
with normal lung function and no history of lung disease. 
 
2.2. Lung tissue samples 
Lung tissue specimens were collected from patients of the HUH (Ohlmeier et al. 2016), that 
was used for the proteomic study. Samples from non-smokers and smokers without or with 
mild to severe COPD (stage I–III) were obtained from tumor-free peripheral lung in operations 
for local tumors. Lung specimens with very severe COPD (stage IV), IPF, and AATD were 
obtained from lung transplantations (Ohlmeier et al. 2016).  Malignancy had been excluded 
 
 
(Ohlmeier et al. 2016). The history of smoking is 10 years in smokers with and without 
COPD (Ohlmeier et al. 2016). 
 
3. Sample collection 
 
3.1. Sputum induction and processing 
According to the ERS Task Force and described in detail previously (Djukanovic et al. 2002, 
Kelly et al. 2002), sputum was induced by inhalation of 4.5% hypertonic saline at 5-minute 
intervals for a maximum of 20 minutes, after the participants cleaned their mouths and noses. 
Control and healthy smoker subjects did not use any premedication before induction, whereas 
patients with COPD used 200 μg salbutamol (GSK) as premedication. After induction, sputum 
without salivary contamination was treated with dithioerythritol (DTE, Sigma, Munich, 
Germany) then mixed for 30 minutes. The homogenised sputum was further centrifuged at 
400g for 10 minutes to separate the supernatant from the cell pellet. Cell viability was verified 
with trypan blue in a Burker chamber using the resuspended pellet with phosphate-buffered 
saline (PBS) (Louhelainen et al. 2010). Cytospins (Thermo Scientific, Wilmington, DE, USA) 
were performed on the resuspended pellet after centrifugation at 400g for 6 minutes. Coded 
cytospins were stained by May-Grunwald-Giemsa staining (MGG) (Merck, Darmstadt, 
Germany). The acceptable criteria for each cytospin were based on squamous epithelial cells 
below 70% per 400 cells. The acceptable cytospins were frozen at -20°C (Louhelainen et al. 
2010). Our group technician (Tiina Marjomaa) was responsible for collecting the sputum in 
Helsinki and teaching sputum processing in Rovaniemi. 
 
3.2. Plasma collection and processing 
Peripheral whole venous blood and sputum samples were collected at the same visit day for 
the individual. Whole blood in EDTA tubes was centrifuged at 400g for 10-15 minutes to 
prepare plasma. The plasma samples were frozen at -80°C until analysed. 
 
4. Lung function measurement 
 
Standard spirometry and the diffusing capacity of the lung for carbon monoxide (DLCO) were 
performed according to ATS/ERS recommendations (Enright et al. 2008). Spirometry values 
were assessed by standard spirometry (Medikro M 903/4, Medikro Oy, Kuopio, Finland). In 
addition, the Finnish cohort used data from published Finnish research as a reference value 
(Viljanen et al. 1982). All participants were tested. 
 
 
 
 
 
5. Laboratory methods 
 
5.1. Two-dimensional difference gel electrophoresis (2D-DIGE) (Study I-II) 
Lung tissues obtained from non-smokers, smokers, COPD, AATD or IPF were purified by 
acetone precipitation. Supernatant protein was quantified according to the manufacturer's 
protocol using a Bradford-based Roti-Nanoquant (Roth, Karlsruhe, Germany). Protein extracts 
were labelled using the CyDye DIGE Fluor labelling kit (saturation DIGE, GE Healthcare, 
Piscataway, NJ, USA). Isoelectric focusing (IEF) after anodic sample cup loading was 
performed with the Multiphor II system (GE Healthcare). SDS-PAGE was performed 
overnight with the Ettan DALT II system (GE Healthcare). 2-D gels were scanned with a 
Typhoon 9400 imager (GE Healthcare) to detect fluorescence signals and were analysed with 
the 2-DE image analysis software Delta2D 4.3 (Decodon, Greifswald, Germany). According 
to the known protein sequence, theoretical spot positions were calculated with the Compute 
pI/Mw tool (http://web.expasy.org/compute_pi/). The spot positions were further analysed by 
the 2-DE image analysis software Melanie 3.09 (GeneBio, Geneva, Switzerland) 
 
5.2. Mass spectrometry (MS) (Study I and II) 
Additional 2-D gels were run with the unlabelled protein (400-600 μg) combined with Cy3-
labeled internal standard (5 μg, Ohlmeier et al. 2016) for protein identification. The proteins 
were analysed and matched with the 2-DE image analysis software Melanie 3.09 (GeneBio, 
Geneva, Switzerland). The matched spots were further excised and digested with trypsin 
(recombinant, Roche, Switzerland) and prepared as previously described (Hallstrand et al. 
2010). Peptide masses were analysed using MALDI-TOF/TOF (UltrafleXtreme, Bruker, 
Billerica, USA). Theoretical spot positions were calculated according to their spot-specific 
peptide mass fingerprint or peptide sequence (or both) with the bioinformatic tool BioTools 
Version 3.2 (Bruker). The following search parameters were used: MS tolerance, 30 ppm; 
MSMS tolerance, 0.7 Da; enzyme, Trypsin; engine, Mascot version 2.4.0.; database, NCBInr; 
modifications, carbamidomethyl  and optional oxidation of Met, up to one missed cleavage. 
 
5.3. Western blot analysis (Study I and II) 
Lung tissue homogenates (Ishikawa et al. 2010) (n=42, Study I and II) and sputum supernatants 
(n=42, Study II) were analysed by Western blotting. Ponceau S staining (Sigma Aldrich, USA) 
was used to standardize the loading of the sputum and lung homogenates (Ohlmeier et al. 2010) 
to avoid problems with the conventional loading markers in COPD (Casado et al. 2007, Glare 
et al. 2002, Rabe et al. 2007, Gao et al. 2015). The monoclonal antibodies mouse cathepsin D 
(CTSD) (BD Transduction Laboratories, USA), mouse collapsin response mediator protein-2 
(CRMP2)/dihydropyrimidinase-related protein 2 (DPYSL2) (Immuno-Biological Laboratories, 
USA), rabbit TGM2 and rabbit tripeptidyl-peptidase 1 (TPP1) (Cell Signaling Technology, 
Danvers, USA) were used in Study I. BPIFA1 (MAB1897) monoclonal antibodies (RD 
 
 
Systems, Minneapolis, USA), polyclonal BPIFB1-1 and BPIFB1-2 antibodies (Bingle et al. 
2010) were used in Study II.  Immunodetection was performed by the chemiluminescent HPR-
substrate immune-detection kit (Millipore, USA). Membranes were exposed to X-ray film 
(Fujifilm, Tokyo, Japan). ImageJ software was used in further analysis and calculation. 
 
5.4. Immunohistochemistry and histochemistry (Study II) 
Lung tissue was fixed by formalin and then embedded in paraffin. The prepared tissues were 
further cut into serial sections (4 μm) and stained (Bingle et al. 2010, Bingle et al. 2007). 
Detection was performed with anti-rabbit biotin-labelled secondary antibody from the 
Vectastain Elite ABC kit (Vector Laboratories, USA). Rabbit IgG (DAKO, USA) was used as 
a negative control. Positive cells were stained red though peroxidase enzymatic development 
using Vector NovaRed substrate kit. Sections were counterstained with haematoxylin, 
dehydrated with xylene and mounted in DPX. Alcian blue staining of acidic mucins was 
performed by a standard histological method (Gao et al. 2016). 
 
5.5. Development of a functional ELISA (Study III)  
Since no commercial ELISA kit was available for BPIFB1, we developed a functional ELISA 
for detecting BPIFB1 concentration in sputum based on a previous study (Bingle et al. 2010). 
The detection range of the assay was 0.5- 20 μg/ml and the lowest standard was 312 ng/ml.  
BPIFB1-1 and BPIFB1-2 antibodies were produced in rabbits by Genscript (Piscataway, USA) 
against the peptides C+AQATIRMDTSASGPTRLVLS and 
C+KDALVLTPASLWKPSSPVSQ (corresponding to BPIFB1-1 residues 137-156 and 
BPIFB1-2 residues 465-484) (Bingle et al. 2010, Gao et al. 2015). The antibodies were purified 
by affinity chromatography and the rabbit anti-BPIFB1-2 antibody was biotinylated with 
Lightning Link kit (704-0010, Innova Biosciences, UK) (Gao et al. 2015). The anti-BPIFB1-1 
antibody was captured on microtiter plates (MaxiSorp NUNC immuno module, Thermo 
Scientific, USA) overnight at 4°C. Nonspecific binding sites were blocked with 1% BSA-PBS 
for 2 hours at room temperature. The general diluted concentration was 1:20 for samples and 
standards (recombinant human BPIFA1, 13275-H08H, Sino Biological). A 1:200 dilution was 
used if the concentration exceeded the detection range. The prepared samples and standards 
were incubated as duplicates for 1 hour with gentle shaking. Bound BPIFB1 was measured 
using biotinylated rabbit anti-BPIFB1-2 and Eu-labelled streptavidin (1244-360, Perkin Elmer, 
Finland). Delfia enhancement solution (118-100, Perkin Elmer, Finland) was added. 
Fluorescence of europium was detected with an EnVision Xcite fluorometer (Perkin Elmer, 
Finland). 
 
 
 
 
 
 
5.6. Commercial ELISA (Study I-V) and Magnetic Human High Sensitivity Luminex assay 
(Luminex assays, Study V)  
For the measurement of TGM2, sRAGE, high mobility group box 1 (HMGB1), SP-A, MPO, 
NGAL, YKL-40 and IL-13 (Study I-V) commercially available ELISA kits (LifeSpan 
BioSciences, Seattle, USA; RD Systems, Minneapolis, USA; Uscn Life Science, Wuhan, 
China; Kokusai-F kit Sysmex, Kobe, Japan; Abnova Inc. Walnut, USA; Uscn Life Science, 
Wuhan, China; Uscn Life Science, Wuhan, China; RD Systems, Minneapolis, USA) were used 
according to the manufacturers’ instructions. IL-6 levels were measured by Magnetic Human 
High Sensitivity Luminex assay (RD Systems, Inc. Minneapolis, USA) according to the 
manufacturers’ instructions. The detection limits were: 0.156 ng/ml for TGM2, 78 pg/mL for 
sRAGE, 0.238 ng/mL for HMGB1, 1 ng/mL for SP-A, 0.78 ng/mL for MPO, 39 pg/mL (Study 
IV) and 17 pg/mL for NGAL (Study IV), 3.55 pg/mL for YKL-40, 5.7 pg/mL for IL-13 and 
0.14 pg/mL for IL-6, respectively. 
 
6. Statistical analyses 
 
The distribution of basic subject characteristics is shown as mean ± standard deviation (SD, 
Study I-IV), mean ± standard error (SEM, Study V) or as percentages, if not stated otherwise. 
Biomarker concentrations as are shown as mean ± SEM or median ± interquartile range. 
Comparisons between groups were evaluated by analysis of variance (ANOVA) (Study I, III 
and V), χ2-Test (Study I) and t-test (Study III). The data for groups was also analysed by the 
Kruskal-Wallis test followed by the Mann-Whitney U test (Study I, II and V). Linear regression 
analysis was used to assess the association between TGM2 levels and COPD severity or lung 
function in Study I. Intra-assay coefficient of variation (CV) and inter-assay CV% were 
determined for the functional BPIFB1 ELISA in study II. The intra-assay CV% was calculated 
in one plate, while the inter-assay CV% was analysed between different plates. Multivariate 
stepwise regression analysis was performed in Studies III, IV and V to obtain the variables to 
model ACOS. The biomarkers were further analysed by area under the curve (AUC) statistics 
to assess their predictive ability to distinguish ACOS from COPD and ACOS and COPD from 
asthma in Study IV. AUC was also used to distinguish ACOS from asthma, and ACOS from 
asthma and COPD in Study V. Raw data was used in the comparisons within each cohort and 
standardised data (Z-scores) in the comparisons between the two cohorts (Study V). 
Spearman's rank correlation was used to evaluate the associations between biomarker 
concentrations with other variables (Study I-V). All statistical analyses were performed with 
the SPSS software program (version 16.0, 20.0 and 21.0, SPSS Inc., Chicago, IL, USA). 
GraphPad Prism (version 6.0, San Diego, USA) was used for statistical analyses in Studies I 
and II. A p-value of <0.05 was considered statistically significant. 
 
 
 
 
RESULTS 
 
1. Subject characteristics  
 
The main demographic characteristics of the subjects are shown in Table 3 (Study I-V). The 
sputum cell counts and spirometry data are shown in Table 4. Smokers with COPD had lower 
FEV1 than the other two groups, and smokers had lower post-bronchodilator FEV1/FVC than 
non-smokers (Study I, II and III). The post-bronchodilator FEV1/FVC was over 0.70 in IPF 
patients (Study II). In the Finnish discovery cohort, patients with COPD and ACOS had more 
pack-years and significantly lower FEV1 than the asthma groups (Study IV and V). The levels 
of pack-years and neutrophil and eosinophil percentages in ACOS in the discovery cohort were 
as similar as those in the replication cohort (Study V).  
 
2. Potential biomarkers in early diagnosis of COPD  
 
2.1. TGM2 in mild-moderate COPD (Study I) 
2.1.1. Proteomic changes in lung tissue 
Lung tissue samples were analysed using 2D-DIGE in non-smokers, smokers, smokers with 
mild to moderate COPD (stages I-II) and with very severe COPD (stages III-IV), AATD and 
IPF (Figure 3). TGM2 and CTSD were observed in COPD-specific expression profiles. TGM2 
levels were highest in COPD stages III-IV, whereas TGM2 levels were not elevated in smokers. 
CTSD levels were highest in COPD stages I-II, and the levels were also increased in smokers 
compared with controls. Macrophage-capping protein (CAPG), DPYSL2 and TPP1 
represented putative changes. CAPG and TPP1 levels were increased in COPD stages I-II and 
smokers when compared with non-smokers.  
 
2.1.2. Sputum and plasma TGM2 levels in smokers and COPD 
TGM2 in sputum and plasma was further investigated in a larger cohort (n=120, Figure 4). 
TGM2 levels in sputum and plasma were significantly increased in smokers with COPD (stages 
II-III) than in smokers (p=0.004 and p=0.007, respectively) and in non-smokers (p=0.005 and 
p=0.033, respectively). There were no significant differences in sputum TGM2 levels between 
smokers with COPD stage I and smokers (p>0.05), whereas plasma TGM2 levels were 
increased in COPD stage I compared with smokers (p=0.008). 
 
2.1.3. Correlation between TGM2 and clinical variables  
Sputum and plasma TGM2 levels both were correlated with FEV1% predicted and FEV1/FVC 
in all subjects. Sputum TGM2 levels also were correlated with FVC, FEV1, age and pack-years 
in univariate analysis (Table 5). In linear regression analyses of smokers, age was an 
 
 
independent factor for sputum TGM2 (p=0.038), whereas gender and pack-years were not a 
confounding factor (p>0.05 for both).   
 
Table 3: Subject characteristics in this work 
  Subject Gender Age Pack-years Smoking status 
  n F/M     Ex-/current- 
Study I          
Lung tissue study           
Non-smokers  9 7/2 60 0 0 
Smokers 9 5/4 66 43 3/6 
COPD I-II 8 1/7 62 43 2/6 
COPD III+ 8 4/4 59 31 3/5 
AATD 8 4/4 57 28 3/NA 
IPF 9 2/7 55 12 3/NA 
Sputum and plasma studies          
Non-smokers  25 18/7 56 0 0 
Smokers 46 26/20 49 26 10/36 
COPD I-II 24 5/19 55 34 2/22 
COPD II-III 25 3/22 62 43 8/17 
Study II           
Sputum study (baseline; follow-
up)          
Non-smokers 31; 31 21/10; 21/10 56; 58 0 0 
Smokers without COPD 169; 145 81/88; 68/77 52; 55 29; 32 39/130; 33/112 
Smokers with COPD 52; 70 7/45; 19/51 59; 62 39; 40 11/41; 20/50 
Lung tissue study (set 1; set 2)          
Non-smokers 14; 4 7/7; 4/0 64; 70 0 3/0; NA 
Smokers without COPD; IPF 14; 4 5/9; 0/4 61; 56 30; NA 1/13; NA 
Smokers with COPD 14; 5 7/7; 2/3 61; 60 40; 27 NA/11; 3/1 
Study III (baseline)           
Non-smokers 32 22/10 56 0 0 
Smokers without COPD 212 103/109 52 28 44/168 
Smokers with COPD 51 9/42 59 38 12/39 
Study IV          
Non-smokers  26 10/16 47 0 0 
Health smokers 23 11/12 48 26 0/23 
Asthma 32 16/16 58 16 17/4 
COPD 39 13/26 62 48 13/26 
ACOS 14 5/9 61 37 8/6 
Study V (discovery; replication)          
Non-smokers 14; 22 5/9; 13/9 16; 58 0; 0 0/0; NA 
Health smokers 14; 40 5/9; 5/35 48; 63 27; 37 0/14; NA 
Asthma 24; 21 15/9; 17/4 58; 42 13; 4 9/6; NA 
COPD 20; 35 8/12; 1/34 59; 72 37; 48 7/12; NA 
ACOS 18; 17 6/12; 3/14 62; 66 43; 41 11/7; NA 
 
 
Table 4: Sputum cell counts and spirometry data in this work 
  Neutrophils % 
Eosinophils 
% 
Macrophages 
% 
FEV1/FVC 
% 
FEV1 
% 
Study I          
Sputum and plasma 
studies          
Non-smokers  24 NA 27 85 106 
Smokers 35 NA 22 82 97 
COPD I-II 40 NA 24 67 87 
COPD II-III 45 NA 28 60 63 
Study II           
Sputum study (baseline; 
          
 follow-up) 
Non-smokers 22; NA NA 23; NA 86; 82 108; 103 
Smokers without COPD 32; NA NA 24; NA 82; 76 96; 93 
Smokers with COPD 43; NA NA 27; NA 62; 58 74; 71 
Study III           
Plasma study (baseline)     
Non-smokers NA NA NA 84 111 
Smokers without COPD NA NA NA 82 97 
Smokers with COPD NA NA NA 63 74 
Study IV          
Non-smokers  35 2 59 84 104 
Smokers 42 1 54 80 96 
Asthma 53 6 41 81 77 
COPD 63 1 33 63 58 
ACOS 68 8 22 70 55 
Study V (discovery; 
replication)           
Non-smokers 37; 64 2; 3 NA 84; 83 106; 96 
Smokers 43; 70 0; 2 NA 81; 77 99; 94 
Asthma 54; 46 5; 12 NA 77; 81 79; 95 
COPD 63; 72 2; 3 NA 56; 60 58; 70 
ACOS 65; 66 7; 9 NA 56; 55 52; 64 
 
 
Table 5: Correlation of plasma and sputum TGM2 with demographics  
  Plasma TGM2  Sputum TGM2 
  r P-value r P-value 
Age 0.027 0.772  0.220 0.016 
Pack-years V2 (n=95) 0.158 0.475 0.229 0.029 
Post-bronchodilator 
FVC % -0.098 0.285 -0.182 0.047 
FEV1 L -0.119 0.194 -0.201 0.028 
FEV1 % predicted -0.233 0.010 -0.291 0.001 
FEV1/FVC %  -0.237 0.009 -0.260 0.004 
 
Table 5 is modified from table in Ohlmeier et al.  Am J Physiol Lung Cell Mol Physiol. 2016. 
 
Figure 3. COPD-specific changes in the human lung tissue proteome 
 
Spot Protein Ratio 
  NS vs. 
    S CI-II CIII-IV AATD IPF 
COPD 
-91 CAPG 2,04 4,43 2,94 (1,56) (2,02) 
138 CTSD 1,69 3,36 2,03 (1,47) (-1,17) 
-139 CTSD 2,37 5,67 (3,04) (1,22) (1,14) 
(93*) 
DPYSL2/ 
2,32 2,01 2,44 (1,49) (1,50) 
CRMP2 
-35 TGM2 (-1,05) 1,45 1,93 (1,16) (1,09) 
36 TGM2 (1,03) 1,58 2,36 (1,41) 1,51 
37 TGM2 (-1,06) 2,00 2,68 1,98 (2,27) 
-87 TPP1 2,18 5,09 3,65 (2,47) 1,81 
Figure 3: Gel parts represent the exact spot positions and expression profiles of the corresponding protein in non-
smokers (NS), smokers (S), smokers with COPD stage I–II (CI–II) and stage III–IV (CIII–IV), α-1-antitrypsin 
deficiency (AATD), and idiopathic pulmonary fibrosis (IPF). The expression profile of the most prominent spot 
(underlined) is shown. Protein fragments are indicated with asterisks and putative changes with brackets. In the 
expression profiles statistically significant changes are indicated, whereas study groups without statistical 
significance are marked with asterisks. Spot numbers according to Fig. 3. Spots with similar molecular weight but 
different charge belonging to the same protein (“spot trains”) are clustered. Ratio corresponds to the change in the 
mean normalized spot volumes when NS, and S, and COPD I–II or COPD III–IV, and AATD and IPF were 
compared. The figure is modified from figure and table in Ohlmeier et al.  Am J Physiol Lung Cell Mol Physiol.
2016. 
2.2. Sputum BPIFB1 levels in smokers and COPD in a longitudinal study (Study II) 
2.2.1. The presence of secreted and glycosylated BPIFB1 isoform 1 in smokers and COPD 
Identification of BPIFB1 by 2D-DIGE and MS using proteins extracted from purified sputum 
from non-smokers, smokers and COPD (Ohlmeier et al. 2012). The elevated BPIFB1 levels in 
sputum had been observed in smokers and COPD (Ohlmeier et al. 2012). In 2D gels, the 
localisation of the two observed BPIFB1 spots (54 kDa) were similar to theoretical localisation 
(52 kDa). The two spots also had similar expression profiles, suggesting the presence of full-
 
length BPIFB1 isoform 1. Glycosylated BPIFB1 in sputum was identified using the shift of the 
55-kDa band to a lower molecular weight after treatment. Furthermore, we clarified that the 
secreted BPIFB1 isoform 1 is the upregulated BPIFB1 in smokers and COPD. 
Figure 4. Sputum and plasma TGM2 levels 
 
Figure 4: Sputum and plasma TGM2 levels in sputum (A) and plasma (B) from non-smokers (NS, n=25), smokers 
(S, n=46), smokers with COPD stage I (CI, n=24) and COPD stage II-III (CII-III, n=25) were measured with 
ELISA. The solid line shows the median value. * p<0.05 and ** p < 0.01. The figure is modified from figure in 
Gao et al. Am J Physiol Lung Cell Mol Physiol. 2015. 
2.2.2. BPIFBA1 and BPIFB1 levels in smokers and COPD 
Immunoblotting was used to investigate the expression of BPIFA1 and BPIFB1 in sputum and 
lung tissue samples (Bingle et al. 2010). There were no significant differences in BPIFBA1
levels among non-smokers, smokers and COPD in sputum and lung tissue. Sputum BPIFB1
levels were increased in COPD compared with non-smokers (p<0.05) and smokers (p=0.006) 
by image analysis, whereas the BPIFB1 levels in lung tissue were higher in COPD compared 
with non-smokers (p=0.006) by Western blot analysis. There was no significant difference 
between COPD and IPF when compared to the BPIFB1 levels in lung tissue (p=0.064). 
Furthermore, sputum BPIFB1 levels at baseline were investigated in a longitudinal cohort 
(n=252) using functional ELISA (Figure 5). Sputum BPIFB1 levels were increased in smokers 
with COPD when compared with smokers without COPD (p=0.007) and non-smokers 
(p<0.001). Based on smoking status at baseline, the smokers and COPD groups were further 
divided into ex-smokers vs. current smokers. Interestingly, sputum BPIFB1 levels were 
significantly elevated in current smokers with COPD when compared with current smokers 
without COPD (p=0.004).  
 
Figure 5: Sputum BPIFB1 levels measured by a newly developed method using an ELISA-
based assay 
 
Figure 5: Sputum levels of BPIFB1 measured by a newly developed method using an ELISA-based assay. (A): 
BPIFB1 levels in sputum samples from non-smokers (n = 31), smokers (n = 169), and smokers with COPD (n = 
52) at baseline. (B): effects of smoking on BPIFB1 levels in the smoker and COPD groups stratified according to 
their smoking status into current smokers (n = 130 and n = 41, respectively) and ex-smokers (n = 39 and n = 11, 
respectively). **p < 0.01 and *** < 0.001. The figure is modified from figure in Gao et al. Am J Physiol Lung 
Cell Mol Physiol. 2015. 
2.2.3. Correlation between BPIFB1 and clinical variables in cross-sectional and longitudinal 
studies 
The study subjects in the non-smokers, smokers without COPD and smokers with COPD 
groups were pooled to analyse the correlation between BPIFB1 concentrations and clinical 
variables in univariate and multivariate analysis. The correlations were mainly analysed in two 
studies: 1). with cross-section variables: BPIFB1 vs. characteristics at baseline. 2). with 
longitudinal variables: BPIFB1 vs. characteristics after a 4-year follow-up and BPIFB1 vs. 
changes in lung function over a 4-year follow-up period. e.g. the value of longitudinal changes 
(Δ).  The cross-section study showed that baseline sputum BPIFB1 levels were correlated with 
BMI, pack-years, FEV1% predicted and FEV1/FVC% in all subjects and were correlated with 
pack-years in smokers with COPD at baseline. In the longitudinal study, baseline sputum 
BPIFB1 levels were correlated with pack-years, FEV1% predicted and FEV1/FVC% in all 
subjects and were associated with FVC% and FEV1% predicted after the 4-year follow-up in 
smokers with COPD. Meanwhile, elevated BPIFB1 levels were correlated with ΔFEV1% 
predicted (p=0.001) and ΔFEV1/FVC% (p=0.012) in smokers with COPD, especially those
levels were associated with ΔFEV1% predicted (0.007) and ΔFEV1/FVC% (p=0.001) in 
 
current smokers with COPD. There was no significant correlation between BPIFB1 levels and 
ΔFEV1 % predicted in all participants. 
2.2.4. BPIFB1 staining is elevated in remodelled airway epithelium in severe COPD 
Lung section samples were further analysed using immunohistochemistry for BPIFB1 and 
MUC5B in non-smokers and in severe COPD.  MUC5B is a goblet cell marker. BPIFB1 and 
MUC5B exhibited strong staining in the airway from severe COPD, no staining was observed 
in non-smokers. In addition, no staining was observed in peripheral lung tissue or within the 
sub-epithelial and fibrotic regions. 
2.3. sRAGE in airway disease in a longitudinal study (Study III) 
2.3.1. Plasma sRAGE and HMGB1 levels at baseline 
Plasma sRAGE levels were significantly lower in smokers without COPD and smokers with 
COPD than in non-smokers (p<0.05 and p<0.05, respectively) (Figure 6). There were no 
significant differences in plasma sRAGE levels between smokers with COPD and smokers 
without COPD. In addition, plasma HMGB1 levels were similar among non-smokers, smokers 
without COPD and smokers with COPD. 
Figure 6: Levels of plasma sRAGE  
 
2.3.2. Correlation between sRAGE and clinical variables in cross-sectional and longitudinal 
studies 
In cross-sectional study, plasma sRAGE levels were correlated with BMI, pack-years, FVC, 
FVC% predicted, FEV1 and FEV1% predicted in all subjects at baseline. Subgroup analysis 
showed that plasma sRAGE concentrations were associated with BMI, FVC, FVC% predicted
and FEV1% predicted at baseline in smokers without COPD. In addition, plasma HMGB1 
Figure 6: Plasma levels of soluble receptor 
for advanced glycation end-products 
(sRAGE) from non-smokers (NS, n=32), 
smokers (S, n=212) and smokers with 
COPD (COPD, n=51). *: p < 0.05. The 
figure is modified from the figure in 
Iwamoto et al. BMC Pulm Med. 2014. 
 
 
levels did not correlate with baseline cross-sectional parameters in all subjects and subgroups. 
In the longitudinal study, reduced sRAGE levels were correlated with longitudinal changes (Δ) 
of FEV1/FVC (ΔFEV1/FVC, p=0.010) in all subjects. Subgroup analysis of smokers with 
COPD showed that plasma sRAGE levels were correlated with ΔFEV1/FVC (p=0.019), and 
that sRAGE levels had a correlation trend with ΔFEV1% predicted (p=0.056). Multivariate 
analysis showed that baseline sRAGE levels are an independent predictor for ΔFEV1/FVC 
(p=0.019). 
 
3. Differences and characterisation of biomarkers for ACOS (Study IV and V) 
 
3.1. COPD-related biomarkers (Study IV and V) 
3.1.1. SP-A and sRAGE as pneumocyte-derived markers in ACOS (Study IV) 
Plasma SP-A levels were increased in the COPD and ACOS groups when compared with the 
asthma (p<0.05 and p<0.01, respectively) and smokers (p<0.05 and p<0.05, respectively) 
groups. SP-A levels in COPD were not significantly different when compared with those in 
ACOS (p=0.124). Based on Spearman's correlation, plasma SP-A levels were correlated with 
age, pack-years, FEV1% predicted, FEV1/FVC%, DLCO, sputum neutrophils and sputum 
eosinophils levels. However, FEV1/FVC was an independent predictor for plasma SP-A in 
multivariate analysis. 
 
Plasma sRAGE levels were decreased in the COPD and ACOS groups when compared with 
asthma groups (p=0.025 and p=0.013, respectively). There were no significant differences in 
sRAGE levels between subgroups (ACOS vs. smokers, p>0.05; ACOS vs. COPD, p>0.05; and 
COPD vs. smokers, p>0.05, respectively). In univariate analysis, plasma sRAGE levels were 
correlated with pack-years, FEV1%, DLCO and sputum neutrophil levels.  
 
3.1.2. MPO and NGAL as neutrophil-derived molecules in ACOS (Study IV and V) 
MPO levels did not distinguish COPD from ACOS (p=0.129, Study IV and p=0.128, Study V, 
respectively). In Study V, sputum MPO levels were elevated in ACOS compared with non-
smokers (p=0.012), smokers (p=0.008) and asthma (p=0.004) in the Finnish discovery cohort, 
whereas there were no differences in sputum MPO levels among asthma, COPD and ACOS in 
the Japanese replication cohort (Figure 7).  In relationship analysis in Study IV, sputum MPO 
levels were correlated with age, pack-years, FEV1%, DLCO and sputum neutrophil levels, 
whereas sputum neutrophil levels were an independent predictor for sputum MPO. 
Interestingly, sputum neutrophil levels showed pack-years and age to be independent predictors 
for sputum MPO in the Finnish discovery cohort in in multivariate analysis in Study V.  
 
Sputum NGAL showed highly repeatable results in the Finnish discovery cohort and the 
Japanese replication cohort (Figure 7). In the discovery and replication cohorts, sputum NGAL 
 
levels were significantly higher in ACOS than in asthma (p<0.001 and p<0.001, respectively) 
and COPD (p=0.026 and p=0.002, respectively) (Study V). Sputum NGAL levels in COPD 
were increased compared with those in asthma (p=0.025) in the discovery cohort (Study V). 
Importantly, area under the curve (AUC) statistics showed that sputum NGAL distinguished
ACOS from COPD and asthma in discovery cohort and replication cohort , such as ACOS vs. 
COPD (AUC=0.711, p=0.026 and AUC=0.794, p=0.002, respectively) and ACOS vs. asthma
(AUC=0.833, p<0.001 and AUC=0.840, p<0.001, respectively). In multivariate analysis, 
sputum NGAL levels were independently associated with post-FEV1% predicted (p<0.001) in
Study IV.  In Study V, asthma, COPD, and ACOS groups in both cohorts were pooled to 
analyse the correlations in the univariate and multivariate analyses. Importantly, NGAL levels 
were independently associated with pre-FEV1% predicted in the discovery cohort (p=0.001)
and replication cohort (p=0.002). 
Figure 7: Expression levels of sputum biomarkers (z-scores, median value) in patients with 
asthma, COPD and ACOS in the discovery and replication cohorts 
 
Figure 7: Expression levels of sputum biomarkers in patients with asthma, COPD, and ACOS in the discovery (A) 
and replication cohorts (B) from Asthma (discovery cohort/replication cohort, n=24/21), COPD (n=20/35) and 
ACOS (n=18/17). *: p<0.05; **: p<0.01 and ***: p<0.001. The figure is modified from the figure in Gao et al. 
Int J Chron Obstruct Pulmon Dis. 2016. 
3.2. Asthma-related biomarkers (Study V) 
3.2.1. IL-13 as a type 2 T helper cells marker 
Sputum IL-13 levels were significantly increased in ACOS when compared to smokers 
(p<0.001) in the discovery cohort, whereas these results could not be repeated in replication 
cohort. Meanwhile, increased IL-13 levels in COPD when compared with asthma (p=0.025) in 
 
 
the replication cohort (Figure 7), whereas these results were not replicated  in discovery cohort 
also. Sputum IL-13 levels did not distinguish ACOS from asthma and COPD in both cohorts. 
In multivariate correlation analysis, sputum IL-13 were correlated with pack-years in the 
replication cohort, but not in the discovery cohort. 
 
3.3. Other potential biomarkers (Study V) 
3.3.1. IL-6 as a biomarker of impaired lung function in ACOS  
In the discovery cohort, promising sputum IL-6 levels were observed in ACOS (Figure 7), 
including ACOS vs. asthma (p<0.001) and ACOS vs. COPD (p=0.006). Sputum IL-6 levels 
were also significantly increased in COPD when compared with asthma (p=0.034). 
Furthermore, sputum IL-6 differentiated ACOS from COPD and asthma (AUC >0.7). However, 
these results could not be repeated in the replication cohort. In addition, sputum IL-6 were 
correlated with pre-FEV1% predicted and pack-years in the discovery cohort. There was no 
significant correlation between IL-6 and clinical variables in the replication cohort. 
 
3.3.2. YKL-40 as a biomarker of airway inflammation in ACOS  
In the discovery cohort, sputum YKL-40 levels were significantly increased in ACOS 
compared with non-smokers (p<0.001), smokers (p<0.001), asthma (p=0.001) and COPD 
(p=0.002). ROC analysis showed sputum YKL-40 could distinguish ACOS from COPD and 
asthma (AUC >0.7). In univariate and multivariate analyses, YKL-40 strongly was correlated 
with age and pre-FEV1%. However, there was no significant difference in sputum YKL-40 
levels among groups in the replication cohort (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
1. Summary of background and results 
 
The diagnosis of COPD is often too late. With COPD development, late diagnosis could lead 
to poorer outcomes and increased burdens on society. Currently, diagnosis and staging of 
COPD depends on the airflow limitation level (e.g. FEV1) in clinical practice, whereas FEV1 
based COPD diagnosis is a crude measure in individuals (Vestbo et al. 2008). FEV1 maybe 
insensitive to changes in small airway calibre, and a similar FEV1 may also be of a different 
functional status (Vestbo et al. 2008). Although several risk factors for COPD have been 
identified (GOLD 2017), tobacco smoking remains the major environmental risk factor for 
COPD (Brusselle et al. 2011). Smoking time may be associated with the mortality rate of 
COPD (Bai et al. 2017). Smoking cessation is the critical method for prevention and 
maintenance in COPD, which has the greatest capacity to influence the natural history of 
COPD, including lung function trajectory and progression of COPD (GOLD 2017, Bai et al. 
2017). Thus smoking, along with numerous features related to smoking susceptibility and 
smoking status, should be considered when potential COPD biomarkers are evaluated, which 
may assist in identifying the COPD phenotype. Pulmonary rehabilitation is an effective therapy 
in the integrated care of the patient with chronic respiratory disease (Spruit et al. 2013, Evans 
et al. 2017). Exercise-based pulmonary rehabilitation has proven to reduce exacerbations, 
subjective dyspnoea, and frequency for re-hospitalization (Katajisto et al. 2017, Casaburi et al. 
2009, Garcia-Rio et al. 2009). To date, the existing medications are effective therapy for COPD, 
but it could not modify the long-term reduced lung function (GOLD 2017, Burge et al. 2000, 
Anthonisen et al. 1994, Pauwels et al. 1999, Vestbo et al.1999). ACOS has been confirmed as 
one of the clinical phenotypes of COPD and is associated with poorer outcomes than those in 
patients with asthma and COPD alone, especially in smokers and the elderly.  
 
Therefore, the first project of this thesis intended to investigate novel stable biomarkers for 
early diagnosis of COPD using the longitudinal cohort in sputum,  plasma or both. TGM2, 
sRAGE and BPIFB1 were selected primarily on the basis of our proteomic results using lung 
tissue. Our second project was focused on biomarkers for ACOS using the two cohorts, and 
the aim was to distinguish ACOS from asthma and COPD and to validate our results. We 
investigated biomarkers relevant for airway inflammation from sputum or plasma (or both) in 
asthma (IL-13), COPD (MPO, NGAL, sRAGE and SP-A), or in both asthma and COPD (YKL-
40 and IL-6). The first project confirmed that three potential biomarkers (TGM2, BPIFB1 and 
sRAGE) for COPD development reflect different aspects in disease pathology.  These 
biomarkers had also different correlation with smoking and decline of lung function. In the 
second project, we determined that one of our selected sputum biomarkers might be a 
characteristic feature of ACOS, reflecting both airway inflammation and tissue remodelling. 
 
 
 
2. Proteomics-based specific biomarkers in COPD development (Study I, II and III) 
 
Study I 
Proteomics is a non-biased large-scale screening technique that is an important method for 
investigating COPD pathology (Ohlmeier et al. 2016). We investigated the pathological 
mechanisms of COPD using proteomics (Ohmeier et al. 2008, 2010, 2012, 2016). In study I, 
we detected specific and unspecific changes using lung tissue samples. Although we identified 
82 proteins, only 18 proteins showed disease specificity (Ohlmeier et al. 2016). We verified 
the expression profiles specific to COPD (CTSD, TPP1, CAPG, DPYSL2 and TGM2), AATD 
(e.g. SERPINA1, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hemoglobin subunit 
beta (HBB), and heat shock cognate 71 kDa protein (HSPA8)) and IPF (e.g. annexin A3 
(ANXA3), fatty acid-binding protein (FABP5), HBB, selenium-binding protein 1 (SELENBP1) 
and keratin type II cytoskeletal 7 (KRT7)). The other proteins could reflect the unspecific 
changes, overlapping changes or both (e.g. COPD+AATD, COPD+IPF and AATD+IPF) in 
lung tissue (Ohlmeier et al. 2016). CTSD is present in azurophil granules (Almansa et al. 2012) 
and may be expressed by pulmonary macrophages in response to cigarette smoke (Bracke et 
al. 2012). The expression of CTSD in BALF is elevated in patients with COPD (Tu et al. 2014), 
and gene expression of CTSD and CAPG in blood are both increased in COPD patients with 
critical respiratory illness (Almansa et al. 2012). Consistent with study I, CAPG and CTSD are 
linked to COPD. Our results showed that CAPG, CTSD, DPYSL2 and TPP1 are associated 
with smoking, whereas previous studies revealed that levels of CAPG, CTSD and DPYSL2 are 
increased in lung cancer (Pastor et al. 2013, Pernemalm et al. 2013). These results can be 
partially explained by the observations that smoking is associated with reactive oxygen species 
(ROS) (Kelsen et al. 2008) and is also a known risk factor for COPD and lung cancer.  
 
The most striking finding of study I is related to TGM2, which may be associated to COPD 
onset and severity. TGM2 is a multifunctional enzyme (Ohlmeier et al 2016) and it expressed 
in asthma (Hallstrand et al. 2010), cystic fibrosis (Maiuri et al. 2008), bronchopulmonary 
dysplasia (Witsch et al. 2014) and non-small cell lung cancer (Choi et al. 2011). Although 
TGM2 levels have been analysed in multiple diseases, TGM2 levels have not been investigated 
in COPD (Ohlmeier et al. 2016). In study I, increased levels of TGM2 were detected in the 
moderate-to-severe COPD group compared with those in smokers and in non-smokers with 
different approaches and sample sets (Ohlmeier et al. 2016). In addition, increased levels of 
TGM2 in mild COPD were shown in lung tissue and plasma samples, whereas differences in 
sputum TGM2 levels were not statistically significant between mild COPD and non-smokers, 
although there was an increasing trend in COPD (p=0.075) (Ohlmeier et al. 2016). These 
results suggest that TGM2 may be a promising biomarker for COPD on the basis of COPD 
specificity and concordance with previous results (Ohlmeier et al. 2016). In correlation analysis, 
 
 
sputum TGM2 levels were correlated with age, pack years and lung function, especially lung 
function showed the strongest correlation. As increased age is associated with declined lung 
function in general, we further adjusted the smoking factor in our correlation model. These 
results showed that sputum TGM2 significantly correlates with lung function. Thus based on 
the relationship between TGM2 and lung function, and taking into account its cellular functions 
in transglutaminase crosslinking, G protein signalling and kinase activities, we suggest that 
TGM2 may be related to the disease process itself and is involved in lung tissue remodelling 
(Ohlmeier et al. 2016). Accordingly, TGM2 inhibitors or anti-TGM2 may have therapeutic 
potential in COPD (Ohlmeier et al. 2016). 
 
Study II 
Nashida et co-workers reported that BPIFB1 mRNA was expressed in the palate, lung, and 
nasal epithelium clone protein family (Nashida et al. 2012). Previous proteomic studies have 
shown elevated BPIFB1 levels in cystic fibrosis (Bling et al. 2012), severe uncontrolled asthma 
(Lee et al. 2013) and asthma patients after segmental allergen challenge (Wu et al. 2005). While 
our previous proteomic study investigated BPIFB1 in a smoker cohort (Ohlmeier et al. 2012), 
BPIFB1 levels in COPD have not been previously analysed. In study II, we first detected 
sputum BPIFB1 levels using quantitative analysis in non-smokers, smokers without COPD and 
smokers with COPD (Gao et al. 2015). Furthermore, we examined the relationship between 
BPIFB1 and airflow limitation using a 4-year follow-up cohort (Gao et al. 2015). When 
compared with levels in non-smokers and smokers without COPD, we observed increased 
sputum BPIFB1 levels in smokers with COPD (Gao et al. 2015). BPIFB1 was observed in 
airway goblet cells (Bling et al. 2010), and ciliated epithelial cells are replaced by goblet cells 
when airway irritation increased (Gao et al. 2015). Our immunohistochemistry results 
confirmed that BPIFB1 was located in airway goblet cells, and we further revealed that BPIFB1 
staining is restricted to the airway epithelium (Gao et al. 2015). Together with the quantitative 
results and immunohistochemistry analysis for BPIFB1, it is possible that sputum BPIFB1 
levels may be upregulated in COPD on the basis of enhanced physiological response and 
BPIFB1 protein expression may be maintained in severe disease (Gao et al. 2015). In subgroup 
relationship analysis, increased sputum BPIFB1 levels were correlated with longitudinal 
declined lung function in COPD. In the smoking-related relationship analysis, sputum BPIFB1 
levels were correlated with longitudinal declined lung function in current smokers with COPD 
during the 4-year follow-up period. This correlation was not observed in ex-smokers with 
COPD. Furthermore, sputum BPIFB1 levels showed a strong correlation with pack-years only 
in smokers with COPD. Thus BPIFB1 may be associated with smoking-related pathological 
changes in the airway wall (Gao et al. 2015). Smoking, chronic infection, and enhanced 
immune responses may result in upregulating the BPIFB1 expression in COPD (Gao et al. 
2015). 
 
 
 
We also detected BPIFA1 in sputum and lung tissue in this study. BPIFA1 levels were not 
significantly different between COPD and other groups, but there was an increasing trend in 
COPD compared with those in non-smokers (Gao et al. 2015). Several studies analysed 
BPIFA1 levels (Steiling et al. 2009, Casado et al. 2007) with contradictory results.  Steiling 
and co-workers detected BPIFA1 in airway epithelial cells of current smokers (Steiling et al. 
2009), whereas Casado and co-workers identified BPIFA1 in sputum of patients with COPD, 
but not in smokers (Casado et al. 2007). Together with our BPIFA1 negative results, the more 
systematic studies in larger cohorts are required to clarify the importance of BPIFA1 and 
BPIFB1 in COPD. 
 
Study III  
RAGE is a multiligand signal transduction receptor (Miniati et al. 2011). In soluble forms, 
sRAGE provides protection against inflammation (Miniati et al. 2011) and sRAGE deficiency 
is associated with enhanced inflammation in multiple chronic conditions (Sukkar et al. 2012). 
Several studies have shown that sRAGE expression is reduced in COPD (Smith et al. 2011, 
Sukkar et al. 2012, Miniati et al. 2011). Our previous studies also showed reduced expression 
of sRAGE in patients with COPD, and that full length-RAGE and the C-terminal processed 
variant RAGE were associated with COPD and IPF (Ohlmeier et al. 2010, Iwamoto et al. 2014). 
As the longitudinal study for RAGE was limited, thus our study III aimed to evaluate plasma 
sRAGE and HMGB1 levels in a 4-year longitudinal cohort with 3 groups (non-smokers, 
smokers without COPD and smokers with COPD). To the best of our knowledge, our study 
was the first to compare circulatory HMGB1 levels in smokers and in early COPD without 
comorbidities (Iwamoto et al. 2014). In study III, reduced plasma sRAGE levels were observed 
in smokers with COPD when compared with the corresponding levels in non-smokers 
(Iwamoto et al. 2014). Importantly, this was the first study to reveal the relationship between 
reduced plasma sRAGE levels and progression of airflow limitation, even after controlling for 
demographics and baseline lung function (Iwamoto et al. 2014). sRAGE levels are associated 
with emphysema (Cheng et al. 2013, Cockayne et al. 2012, Coxson et al. 2013, Miniati et al. 
2011), chronic cor pulmonale, neutrophilic airway inflammation in COPD and correlates with 
impaired diffusion capacity (Miniati et al. 2011, Sukkar et al. 2012). The ECLIPSE studies 
confirmed the association between low sRAGE levels and increased emphysema. Circulatory 
sRAGE levels are significantly reduced in COPD patients with advanced GOLD stage (Cheng 
et al. 2013). Another longitudinal study demonstrated that circulatory sRAGE levels correlate 
with decline of lung density in moderate-to-severe COPD using CT scans (Coxson et al. 2013). 
Study III revealed lower plasma sRAGE levels in COPD and suggests that sRAGE may have 
a protective role in the lung (Iwamoto et al. 2014). In addition, most of the COPD patients in 
study III were at the mild-to-moderate stage, which could explain why there were no significant 
differences in plasma sRAGE levels between COPD and smokers and the similar expression 
of plasma HMGB1 between COPD and controls (Iwamoto et al. 2014). As one of the common 
 
 
RAGE ligands, HGMB1 binds Toll-like receptors and activates a pro-inflammatory cascade 
and is associated with inflammation and human airway epithelial cell repair (Ferhani et al. 2010, 
Li et al. 2015, Ojo et al. 2015, Ulloa et al. 2006). Diener and Zhang reported that plasma 
HMGB1 levels are decreased in COPD (Diener et al. 2013, Zhang et al. 2014), whereas another 
study using sputum and plasma demonstrated increased HMGB1 levels in asthma and COPD 
(Hou et al. 2011). In light of these inconsistent results, future large-scale studies are needed to 
further identify the levels and specific roles of HMGB1 in COPD. 
 
3. Promising biomarkers in ACOS studies with two well-defined cohorts (Studies IV and 
V) 
 
To characterise ACOS biomarkers, we investigated seven potential candidates for ACOS in 
the two cohorts in non-smokers, smokers, the patients with asthma, COPD and ACOS, 
including pneumocyte-derived markers (SP-A and sRAGE), neutrophil-derived molecules 
(MPO and NGAL), and Th2 (IL-13), impaired lung function (IL-6) and airway inflammation 
(YKL-40) biomarkers.  
 
Study IV 
To evaluate the utility of COPD-related biomarkers in ACOS, we evaluated the levels of 
plasma SP-A, plasma sRAGE, sputum MPO and sputum NGAL in the Finnish discovery 
cohort (Iwamoto et al. 2014). The levels of SP-A, sRAGE and MPO in ACOS and COPD 
showed a similar pattern when compared with the corresponding levels in asthma. However, 
these biomarkers did not differentiate ACOS from COPD. Overall, AUC statistics revealed 
that all four biomarkers could differentiate ACOS from asthma. However, only sputum NGAL 
levels differentiated ACOS from COPD and asthma. These results suggested that increased 
sputum NGAL levels may be a characteristic feature of ACOS. SP-A is synthesised in alveolar 
type II cells, which are associated with leakage of the lung epithelial barrier (Robin et al. 2002, 
Iwamoto et al. 2014). Our previous study revealed increased plasma SP-A levels in smokers 
and in COPD (Mazur et al. 2011, Ilumet et al. 2011). In study IV, we confirmed increased 
plasma SP-A levels in COPD and the relationship between SP-A and smoking. Further, our 
new findings showed that plasma SP-A levels increased in ACOS compared with those in 
asthma. Moreover, plasma SP-A levels were also associated with lung function and peripheral 
tissue damage. Interestingly, the degree of airway obstruction could be an independent factor 
for SP-A expression (Iwamoto et al. 2014). These results suggested that smoking-induced lung 
injury was strongly associated with both COPD and ACOS. 
 
RAGE can be expressed on AT I pneumocytes and associated with cell adherence and 
spreading (Dahlin et al. 2014, Demling et al. 2006). We investigated plasma sRAGE levels in 
smokers and COPD (Iwamoto et al. 2014). Our current results confirmed our previous results 
 
 
and also revealed that plasma sRAGE levels are decreased in ACOS. Previous evidence 
suggested that reduced plasma sRAGE may be a biomarker for emphysema (Cheng et al. 2013, 
Yonchuk et al. 2015). Consistent with those results, our study demonstrated that plasma 
sRAGE levels are independently associated with DLCO (Iwamoto et al. 2014). In addition, 
plasma sRAGE levels were also associated with smoking, airway limitation and neutrophils. 
Thus our results suggest that peripheral lung destruction may be associated with reduced 
plasma sRAGE in ACOS and COPD (Iwamoto et al. 2014). MPO is a neutrophil marker and 
is released from the primary granules of neutrophils (Iwamoto et al. 2014, Keatings et al. 1997). 
Our results showed that the increased sputum MPO levels were in COPD when compared with 
asthma. The ratio of sputum MPO levels and neutrophils are associated with exacerbations of 
COPD (Liesker et al. 2011). Increased sputum MPO levels have been observed in acute COPD 
exacerbations, which may be evidence of neutrophil activation (Aaron et al. 2001).  Sputum 
neutrophil levels were an independent factor for sputum MPO in our study, which was in a 
good agreement with this. 
 
The most important findings in this study were associated with sputum NGAL. NGAL is a 
neutrophil-related biomarker and is produced by epithelial cells in the respiratory tract 
(Cowland et al. 2003, Bolignano et al. 2008). NGAL inhibits bacterial growth and enhances 
matrix degradation in COPD (Yan et al. 2001). Previously, elevated NGAL levels were also 
shown in bronchial lavage and in plasma from patients with COPD (Eagan et al. 2010, Ekberg-
Jansson et al. 2001). To the best of our knowledge, our study was the first to show increased 
sputum NGAL levels in COPD and ACOS.  This increased sputum NGAL may be produced 
by activated neutrophils and respiratory epithelial cells after inflammatory stimuli (Cowland et 
al. 2003, Karlsen et al. 2010). Moreover, sputum NGAL was significantly elevated in ACOS 
compared with  COPD and was independently associated with airflow obstruction. Thus ACOS 
can be identified by increased levels of sputum NGAL, and NGAL might reflect the enhanced 
neutrophilic airway inflammation or airway epithelial injury (or both) in ACOS (Iwamoto et 
al. 2014).  
 
Study V 
In study V, we investigated five biomarkers to identify inflammatory profiles typical for ACOS 
in the discovery cohort and the replication cohort (Gao et al. 2016). Two biomarkers (NGAL 
and MPO) were selected on the basis of our previous studies (Iwamoto et al. 2014 (1) (2)) and 
the other biomarkers (YKL-40, IL-6 and IL-13) were based on the existing literature. 
Expression of sputum MPO and YKL-40 were not statistically significant different between 
the study groups in the replication cohort, whereas these two biomarkers showed some 
promising results in the discovery cohort. There were no differences in sputum IL-13 levels 
among ACOS, asthma and COPD in both cohorts. While YKL-40, IL-6 and MPO levels in 
ACOS were promising, we were unable to replicate these results in the replication cohort. 
 
 
Serum YKL-40 levels were increased in two clinical phenotypes of asthma (asthma with 
irreversible airway obstruction and asthma with severe exacerbations) (Gomez et al. 2017) and 
in acute exacerbations COPD (Lai et al. 2016). Acute exacerbations in COPD are associated 
with IL-6 (Dickens et al. 2011), and Fu and co-workers observed that there were no significant 
differences in IL-6 levels between ACOS and COPD in serum (Fu et al. 2014). Considering 
IL-6 is a biomarker of systematic inflammation, thus the specificity of IL-6 in airway disease 
may be limited. As a bactericidal compound, MPO diminishes dendritic cell activation and is 
associated with local activation of neutrophils. Accordingly, elevated MPO activity is 
associated with a number of inflammatory diseases (Strzepa et al. 2017, Iwamoto et al. 2014, 
Keatings et al. 1997, Aaron et al. 2001). Our patients with asthma, COPD and ACOS were all 
in stable phase, and the difference of aetiological variability and airway limitation were shown 
in the two cohorts, which could explain the differing results in our study.  
 
The key findings of the study were the following: sputum NGAL showed highly repeatable 
results in the two cohorts, distinguished ACOS from COPD and asthma and independently 
correlated with airflow limitation. NGAL is associated with inflammatory stimuli in respiratory 
epithelial cells (Iwamoto et al. 2014, Cowland et al. 2003) and with Toll-like receptor 
activation during bacterial infections (Flo et al. 2004, Chan et al. 2009). NGAL may also be 
induced by reactive oxygen species in the lung (Roudkenar et al. 2007, Sunil et al. 1009). 
Microbial colonisation and augmented oxidative stress may be involved in ACOS, resulting in 
airway inflammation, airway reactivity, injury and remodelling (Iwamoto et al. 2016). 
Consistent with our study, our validated results confirmed that sputum NGAL showed potential 
in differentiating between asthma, COPD and ACOS and may be associated with acute viral 
infections and exacerbations in ACOS (Iwamoto et al. 2016). Together, our identified sputum 
biomarkers may be candidate molecules for identifying airway inflammation and airway 
remodelling (Iwamoto et al. 2016). 
 
4. The difference between ACOS and ACO and the diagnostic criteria for ACOS in our 
studies (Study IV and V)  
 
ACOS is an important clinical phenotype in chronic airway disease. However, this phenotype 
is currently not clearly defined. The clinical, pathophysiological and genetic features of ACOS 
are poorly understood (Carolan et al. 2013, Hardin et al. 2011, Wardlaw et al. 2005). ACOS 
has been re-defined as asthma-COPD overlap (ACO) based on the newest GINA strategy 
(GINA 2017), which highlighted that ACO is not a single discrete disease (GINA 2017, Bonten 
et al. 2016). The collection of our ACOS project began in 2005, when there was no confirmed 
name and diagnosis criteria  for ACOS available on the basis of GINA strategy. Therefore, in 
study IV, we selected ACOS patients based on asthma diagnosis. This decision was based on 
the British Guidelines on Asthma Management (British Thoracic Society Scottish 
 
 
Intercollegiate Guidelines Network. 2008) and the ATS/ERS Task Force recommendations 
(Laitinen et al. 2009, Miller et al. 2005). COPD defined by irreversible chronic airway 
obstruction using FEV1/ FVC <0.70 or FEV1/FVC% <88% predicted in post-bronchodilator 
spirometry (Iwamoto et al. 2014). However, when we began study V, the GINA strategy 
formally named "ACOS" and described the diagnosis criteria. Therefore we removed the term 
of FEV1/FVC% <88% predicted, selected the age of onset (>40 years) and included all patients 
with a history of smoking. Taken together with the consumption of sputum samples, there were 
some group size differences between study IV and study V in the Finnish cohort. 
 
5. The roles of biomarkers in precision medicine of COPD 
 
COPD and asthma are common CAD, and both are well-known complex heterogeneous 
diseases. The overlapping syndromes have been recognised as one of the phenotypes in COPD 
or asthma. Current guidelines are useful for COPD management, but a ‘one size fits all’ 
approach is insufficient (Bel et al. 2017). Assessment of ‘treatable traits’ could be a vital step 
in precision medicine of CAD. This approach could deconstruct the diseases into individual 
traits that can be measured and modified (Agusti et al. 2016, Bel  et al. 2017) and that could be 
associated with clinical phenotypes of diseases. Biomarker development may be an effective 
approach in precision medicine, which could improve the treatable traits. Investigating the 
biological mechanisms via different molecular pathways or endotypes for COPD may facilitate 
selection of promising biomarkers. Endotypes, biomarkers and clinical characters may 
contribute to distinguishing the clinical phenotype. On the basis of our study, BPIFB1 may be 
a promising biomarker for COPD. We developed a BPIFB1 ELISA kit, which may assist other 
researchers in investigating this biomarker.  So far, several targeted drugs have been developed 
and are used for improving the treatable trait related to eosinophils. This includes new 
therapeutics based on Th2 biomarkers, such as IL-5 receptor alpha (mepolizumab, reslizumab, 
benralizumab) and IL-13 (lebrikizumab, tralokinumab (Mukherjee et al. 2014, Bel et al. 2017). 
Therapy targeting the IL-5 receptor alpha may be effective in long-term management of 
hypereosinophilic syndrome (Busse et al. 2010, Mukherjee et al. 2014). This approach is also 
effective in COPD related to eosinophilic inflammation (Bel et al. 2017). Our study showed 
that NGAL might reflect ACOS characteristics, and could be a potential biomarker for 
improving treatable traits related to neutrophils in CAD. 
 
6. Strengths and limitations of the study 
 
We investigated human samples from multiple well-defined cohorts, including the 6-year 
longitudinal cohort of adult smokers for early diagnosis of COPD studies (Study I, II and III) 
and the Finnish discovery cohort and the Japanese replication cohort for ACOS studies (Study 
IV and V). We used the strict exclusion criteria for both cohorts. In the 6-year longitudinal 
 
 
cohort of adult smokers, none of the participants had any chronic pulmonary or other diseases 
requiring regular medication. In addition, they had no allergies, no risk factors for other 
pulmonary diseases (e.g. known exposures, bronchiectasis, malignancies, and also previous 
lung tuberculosis) and no any lung infections during the last two months before entering the 
study (Toljamo et al. 2015). In the Finnish discovery cohort, the patients with COPD and 
ACOS had no history of α1-antitrypsin deficiency in their family, and no patients were either 
receiving oral steroid treatment or experienced an exacerbation during the month before 
inclusion (Iwamoto et al. 2014). In the early COPD project, we detected proteomic signatures 
related to smoking, COPD, AATD, IPF, overlapping and unspecific changes, and identified 
specific proteins for lung diseases by the longitudinal studies. The correlation between specific 
COPD biomarkers, disease severity, smoking and other clinical characters were further 
evaluated, particularly in mild and moderate COPD. We established a functional ELISA for 
quantitative detection of BPIFB1. Our study firstly evaluated the relationship between plasma 
sRAGE and longitudinal airway obstruction. In the ACOS study, our project was the first study 
to investigate plasma or sputum biomarkers in patients with ACOS using unbiased comparisons. 
We used the discovery cohort and replication cohort in ACOS and our results were validated 
in a different population. Our controls had normal lung function without other exposures.  
 
Aside from the strengths, there were some limitations in our study. In the early phase of the 
project, our lung tissue samples were evaluated and the severity of COPD assessed according 
to the previous GOLD 2010 and classified into four stages (I-IV), but this seems not to be 
sufficient to reflect the heterogeneity of COPD (Toljamo et al. 2015, Gao et al. 2016). On the 
other hand, the follow-up period of 4 years was relatively short, but this was due to the study 
design of a longitudinal analysis among apparently healthy middle-aged to elderly individuals 
(Gao et al. 2015). In the ACOS project, the diagnosis criteria for the discovery and replication 
cohorts were similar but not identical. Accordingly, diagnosis differences may influence the 
comparison of results between the two cohorts. Meanwhile, the sample size in both cohorts 
were limited. Despite several sample types (lung tissue, sputum and plasma) were used, all 
three biological samples do not come from the same subjects. On the other hand, the limitation 
would be a lack of BALF samples that could reflect the inflammation on a level of small 
airways. Our selected biomarkers were measured by quantitative ELISA after the proteomic 
studies, that may contribute to understanding COPD pathology, but further COPD research is 
still needed via other methods (e.g. genomics, transcriptomics and metabolics studies), as 
proteomics may not adequately verify the specificity of the identified changes. Furthermore, 
multivariate stepwise regression analysis was performed for obtaining an independent 
predictor for biomarker or lung function in our studies, but the other statistical methods may 
be needed in future, such as cluster analyses and principal component analysis. 
 
 
 
 
CONCLUSIONS 
 
We identified the 18 proteins in a well-defined cohort in the study I. CTSD, DPYSL2 and TPP1 
seemed to be specific biomarkers for COPD, and these biomarkers are related to smoking. 
TGM2 was another COPD-specific biomarker, and TGM2 was not associated with smoking 
and may thus be associated with the disease process itself. Our results suggest that TGM2 may 
be associated with COPD severity, and may also be used in the future in COPD diagnosis, 
monitoring and targeted therapies.  
 
According to the results received with the ELISA method established in the study, elevated 
sputum BPIFB1 levels were shown in smokers with COPD compared to smokers without 
COPD. Importantly, sputum BPIFB1 levels were significantly associated with longitudinal 
changes of airflow limitation during a 4-year follow-up period, especially in current smokers 
with COPD. Our immunohistochemistry results showed that BPIFB1 localised in regions of 
goblet cell metaplasia and its staining was restricted to the airway epithelium, confirming the 
known function of BPIFB1 in pulmonary immunity. These results suggest that BPIFB1 may 
be involved in the pathogenesis of smoking-related lung diseases 
 
In the longitudinal study set-up, plasma sRAGE levels were significantly lower in smokers 
with and without COPD compared with controls. Our study is the first to longitudinally 
evaluate the relationship between plasma sRAGE and airway obstruction. Our results showed 
that reduced plasma sRAGE levels were significantly correlated with the progression of airflow 
limitation in all subjects and in smokers with COPD. Therefore, our findings suggest that 
RAGE may have a protective role against the progression of smoking-induced lung damage.  
 
In our first ACOS study on the basis of the Finnish single cohort, our results showed that the 
levels of plasma SP-A, plasma sRAGE and sputum MPO that distinguished ACOS from 
asthma, whereas those levels did not distinguish ACOS from COPD. However, only sputum 
NGAL levels were significantly elevated in ACOS compared with those in COPD and asthma 
and was associated with airflow obstruction independent of sputum neutrophil level. These 
results suggest that NGAL may be a characteristic feature of ACOS, reflecting increased 
neutrophilic airway inflammation, airway epithelial injury or both.  
 
In the second ACOS study using the two well-defined independent cohorts, levels of sputum 
IL-6, YKL-40 and IL-13 in the replication cohort were not significantly different between 
groups, which was inconsistent with the results from the discovery cohort. The difference in 
sputum IL-13 levels in the replication cohort was statistically significant between asthma and 
COPD, whereas no difference was observed in the discovery cohort. Consistent with the 
discovery cohort and the previous study, sputum NGAL had diagnostic value in differentiating 
 
 
ACOS from asthma and COPD and independently correlated with declined lung function. 
Together with our previous study IV, our results suggest a relationship between sputum 
biomarkers and ACOS, and NGAL especially may be a potential biomarker for ACOS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FUTURE RESEARCH 
 
On the basis of our results, no biomarker accurately clarified COPD phenotypes, and 
biomarkers solely specific for one disease might be very rare. For our early COPD project, it 
would be very useful to verify the suggested smoking-independent mechanisms of TGM2 
action in the future (Ohlmeier et al. 2016). Although our results suggest that BPIFB1 and 
sRAGE may play important roles in COPD, future large-scale studies are needed to clarify 
these mechanisms and to specify the roles of modulating lung inflammation in COPD (Gao et 
al. 2015, Iwamoto et al. 2014). More studies are needed to investigate the RAGE/HMGB1 
pathway in COPD. For our ACOS project, future studies are needed to determine the diagnostic 
value of these biomarkers in differentiating ACOS from asthma and COPD. Therefore, future 
research of COPD may include genomic, transcriptomic, proteomic and metabolic studies and 
use of other statistical methods (e.g. cluster analyses and principal component analysis). By 
investigating the multi-level biological network in COPD, we could further clarify the 
endotypes based on the different biological mechanisms and identify relevant biomarkers. 
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